1
|
van der Plas MC, Koemans EA, Schipper MR, Voigt S, Rasing I, van der Zwet RGJ, Kaushik K, van Dort R, Schriemer S, van Harten TW, van Zwet E, van Etten ES, van Osch MJP, Terwindt GM, van Walderveen M, Wermer MJH. One-Year Radiologic Progression in Sporadic and Hereditary Cerebral Amyloid Angiopathy. Neurology 2025; 104:e213546. [PMID: 40198864 PMCID: PMC11995281 DOI: 10.1212/wnl.0000000000213546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2024] [Accepted: 02/20/2025] [Indexed: 04/10/2025] Open
Abstract
BACKGROUND AND OBJECTIVES Knowledge on the short-term progression of cerebral amyloid angiopathy (CAA) is important for clinical practice and the design of clinical treatment trials. We investigated the 1-year progression of CAA-related MRI markers in sporadic (sCAA) and Dutch-type hereditary (D-CAA). METHODS Participants were included from 2 prospective cohort studies. 3T-MRI was performed at baseline and after 1 year. We assessed macrobleeds, cerebral microbleeds (CMBs), cortical superficial siderosis (cSS), convexity subarachnoid hemorrhages (cSAHs), white matter hyperintensities (WMH), enlarged centrum semiovale perivascular spaces (CSO-EPVS), and visually stimulated blood oxygenation level-dependent (BOLD) fMRI parameters. Progression was defined as increase in number of macrobleeds or CMBs, new focus or extension of cSS, increase in CSO-EPVS category, or volume increase of >10% of WMH. Multivariable regression analyses were performed to determine factors associated with progression and the association between events related to parenchymal injury (cSAH, macrobleeds) and radiologic progression. RESULTS We included 98 participants (47% women): 55 with sCAA (mean age 70 years), 28 with symptomatic D-CAA (mean age 59 years), and 15 with presymptomatic D-CAA (mean age 45 years). Progression of >1 MRI markers was seen in all 83 (100%) participants with sCAA and symptomatic D-CAA and in 9 (60%) with presymptomatic D-CAA. The number of CMBs showed the largest progression in sCAA (98%; median increase 24) and symptomatic D-CAA (100%; median increase 58). WMH volume (>10% increase in 70%; mean increase 1.2 mL) was most progressive in presymptomatic D-CAA. A decrease in the upslope of the visually evoked BOLD response was observed for most patients. Symptomatic D-CAA status was associated with more overall progression (adjusted odds ratio [aOR] 9.7; 95% CI 1.7-54.2), CMB (adjusted relative risk [aRR] 2.47; 95% CI 1.5-4.1), and WMH volume progression (β 2.52; 95% CI 0.3-4.8). Baseline CMB count (aRR 1.002; 95% CI 1.001-1.002) was associated with CMB progression and cSS presence at baseline (aOR 8.16; 95% CI 2.6-25.4) with cSS progression. cSS progression was also associated with cSAH and macrobleeds (aOR 21,029; 95% CI 2.042-216.537). DISCUSSION CAA is a radiologically progressive disease even in the short-term. After 1 year, all symptomatic and most of the presymptomatic participants showed progression of at least 1 MRI-marker. CMBs and WMH volume (in symptomatic CAA) and WMH volume (in presymptomatic CAA) are the most promising markers to track short-term progression in future trials.
Collapse
Affiliation(s)
| | - Emma A Koemans
- Department of Neurology, Leiden University Medical Center, the Netherlands
| | - Manon R Schipper
- Department of Radiology, Leiden University Medical Center, the Netherlands
| | - Sabine Voigt
- Department of Neurology, Leiden University Medical Center, the Netherlands
| | - Ingeborg Rasing
- Department of Neurology, Leiden University Medical Center, the Netherlands
| | | | - Kanishk Kaushik
- Department of Neurology, Leiden University Medical Center, the Netherlands
| | - Rosemarie van Dort
- Department of Neurology, Leiden University Medical Center, the Netherlands
| | - Sanne Schriemer
- Department of Neurology, Leiden University Medical Center, the Netherlands
| | - Thijs W van Harten
- Department of Radiology, Leiden University Medical Center, the Netherlands
| | - Erik van Zwet
- Department of Biomedical Data Sciences, Leiden University Medical Center, the Netherlands; and
| | - Ellis S van Etten
- Department of Neurology, Leiden University Medical Center, the Netherlands
| | | | - Gisela M Terwindt
- Department of Neurology, Leiden University Medical Center, the Netherlands
| | | | - Marieke J H Wermer
- Department of Neurology, University Medical Center Groningen, the Netherlands
| |
Collapse
|
2
|
Maury A, Benzakoun J, Bani-Sadr A, Ter Schiphorst A, Reiner P, Hosseini H, Seners P, Pallud J, Oppenheim C, Calvet D, Charidimou A, Varlet P, Turc G, Baron JC. Diagnostic Accuracy of Finger-Like Projections and Subarachnoid Hemorrhage for Cerebral Amyloid Angiopathy: Pathological Validation From Lobar Hematoma Evacuation or Brain Biopsy. Stroke 2025. [PMID: 40270245 DOI: 10.1161/strokeaha.124.050159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2024] [Revised: 03/24/2025] [Accepted: 04/09/2025] [Indexed: 04/25/2025]
Abstract
BACKGROUND Diagnosing cerebral amyloid angiopathy (CAA) after spontaneous lobar intracerebral hemorrhage has significant clinical implications. A previous postmortem study found that the presence of both subarachnoid hemorrhage (SAH) and hematoma finger-like projections (FLP) on acute-stage computed tomography strongly rules in CAA. In the present study, we assessed the diagnostic value of these imaging markers against histopathologic diagnosis in less severe presentations. METHODS This retrospective (2002-2022) multicenter study included patients aged ≥45 years with lobar intracerebral hemorrhage of unknown cause, for whom acute-stage computed tomography or magnetic resonance imaging and neuropathological samples from hematoma evacuation or biopsy were available. Centralized consensus reading (2 raters) of imaging and neuropathological data (including Aβ immunohistochemistry) were performed. Analysis was restricted to samples containing at least 10 vessels. The diagnostic performance was evaluated against the neuropathological reference, that is, CAA/no CAA. RESULTS We analyzed data from 66 patients (age, 65±9 years; men, 33%; hematoma volume, 45±26 mL; death within 1 year, 14%) from 6 French centers. Neuropathological material included samples from hematoma evacuation (n=48) and biopsy (n=18). CAA was present in 38 patients (58%), and FLP and SAH were observed in 29 (44%) and 50 (76%) patients, respectively. FLP had a sensitivity of 0.58 (95% CI, 0.41-0.74) and a specificity of 0.74 (95% CI, 0.54-0.89) for the diagnosis of CAA. SAH demonstrated a high sensitivity of 0.92 (95% CI, 0.78-0.98; negative predictive value=0.80 [0.52-0.96]) but moderate specificity of 0.43 (95% CI, 0.24-0.63). The combined presence of FLP and SAH had a specificity of 0.54 (95% CI, 0.37-0.71) and a sensitivity of 0.79 (95% CI, 0.59-0.92). CONCLUSIONS This study is the first to evaluate the diagnostic performance of FLP and SAH with histopathologic reference in nonautopsied patients. The results suggest these markers have lower diagnostic performance than previously reported in severe hematomas leading to early death. However, the high sensitivity of SAH suggests its potential clinical utility in ruling out CAA when absent.
Collapse
Affiliation(s)
- Alexandra Maury
- Department of Neurology, GHU Paris Psychiatrie et Neurosciences, Université Paris Cité, France. (A.M., D.C., G.T., J.-C.B.)
- Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, France (A.M., J.B., A.S., P.S., J.P., C.O., D.C., P.V., G.T., J.-C.B.)
| | - Joseph Benzakoun
- Department of Imaging, GHU Paris Psychiatrie et Neurosciences, Université Paris Cité, France. (J.B., C.O.)
- Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, France (A.M., J.B., A.S., P.S., J.P., C.O., D.C., P.V., G.T., J.-C.B.)
| | - Alexandre Bani-Sadr
- Department of Neuroradiology, East Group Hospital, Hospices Civils de Lyon, CREATIS, CNRS UMR 5220, INSERM U 5220, Claude-Bernard Lyon I University, France (A.B.-S.)
| | - Adrien Ter Schiphorst
- Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, France (A.M., J.B., A.S., P.S., J.P., C.O., D.C., P.V., G.T., J.-C.B.)
- Department of Neurology, CHRU Gui de Chauliac, Montpellier, France (A.S.)
| | - Peggy Reiner
- Department of Neurology, Hôpital Lariboisière, APHP Nord, INSERM UMR-S 1144, FHU NeuroVasc, Paris, France (P.R.)
| | - Hassan Hosseini
- Department of Neurology, H. Mondor University Hospital, Créteil, France (H.H.)
| | - Pierre Seners
- Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, France (A.M., J.B., A.S., P.S., J.P., C.O., D.C., P.V., G.T., J.-C.B.)
- Department of Neurology, Rothschild Foundation Hospital, Paris, France (P.S.)
| | - Johan Pallud
- Department of Neurosurgery, GHU Paris Psychiatrie et Neurosciences, Université Paris Cité, France. (J.P.)
- Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, France (A.M., J.B., A.S., P.S., J.P., C.O., D.C., P.V., G.T., J.-C.B.)
| | - Catherine Oppenheim
- Department of Imaging, GHU Paris Psychiatrie et Neurosciences, Université Paris Cité, France. (J.B., C.O.)
- Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, France (A.M., J.B., A.S., P.S., J.P., C.O., D.C., P.V., G.T., J.-C.B.)
| | - David Calvet
- Department of Neurology, GHU Paris Psychiatrie et Neurosciences, Université Paris Cité, France. (A.M., D.C., G.T., J.-C.B.)
- Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, France (A.M., J.B., A.S., P.S., J.P., C.O., D.C., P.V., G.T., J.-C.B.)
| | - Andreas Charidimou
- Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, MA (A.C.)
| | - Pascale Varlet
- and Department of Neuropathology, GHU Paris Psychiatrie et Neurosciences, Université Paris Cité, France. (P.V.)
- Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, France (A.M., J.B., A.S., P.S., J.P., C.O., D.C., P.V., G.T., J.-C.B.)
| | - Guillaume Turc
- Department of Neurology, GHU Paris Psychiatrie et Neurosciences, Université Paris Cité, France. (A.M., D.C., G.T., J.-C.B.)
- Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, France (A.M., J.B., A.S., P.S., J.P., C.O., D.C., P.V., G.T., J.-C.B.)
| | - Jean-Claude Baron
- Department of Neurology, GHU Paris Psychiatrie et Neurosciences, Université Paris Cité, France. (A.M., D.C., G.T., J.-C.B.)
- Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, France (A.M., J.B., A.S., P.S., J.P., C.O., D.C., P.V., G.T., J.-C.B.)
| |
Collapse
|
3
|
Seiffge DJ, Paciaroni M, Auer E, Saw J, Johansen M, Benz AP. Left Atrial Appendage Occlusion and Its Role in Stroke Prevention. Stroke 2025. [PMID: 40248892 DOI: 10.1161/strokeaha.124.043867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/19/2025]
Abstract
Atrial fibrillation is a frequent cardiac arrhythmia and is associated with an increased risk of cardioembolic stroke. The left atrial appendage is a finger-like extension originating from the main body of the left atrium and the main location of thrombus formation in patients with atrial fibrillation. Surgical or percutaneous left atrial appendage occlusion (LAAO) aims at preventing clot formation in the left atrial appendage. Here, we describe available surgical and percutaneous approaches to achieve LAAO and discuss the available evidence for LAAO in patients with atrial fibrillation. We discuss the role of LAAO and its role in stroke prevention in frequent scenarios in cerebrovascular medicine: LAAO as a potential alternative to oral anticoagulation in patients with a history of intracranial hemorrhage, and LAAO as a promising add-on therapy to direct oral anticoagulant therapy in patients with breakthrough stroke despite anticoagulation. Finally, we provide an outlook on currently ongoing trials that will provide further evidence in the next years.
Collapse
Affiliation(s)
- David J Seiffge
- Department of Neurology, Inselspital University Hospital and University of Bern, Switzerland (D.J.S., E.A.)
| | - Maurizio Paciaroni
- Department of Neurosciences and Rehabilitation, University of Ferrara, Italy (M.P.)
| | - Elias Auer
- Department of Neurology, Inselspital University Hospital and University of Bern, Switzerland (D.J.S., E.A.)
- Graduate School for Health Sciences, University of Bern, Switzerland (E.A.)
| | - Jacqueline Saw
- Division of Cardiology, Vancouver General Hospital, University of British Columbia, Canada (J.S.)
| | - Michelle Johansen
- Department of Neurology, Cerebrovascular Division, John Hopkins University School of Medicine, Baltimore, MD (M.J.)
| | - Alexander P Benz
- Population Health Research Institute, McMaster University, Hamilton, Canada (A.P.B.)
- Department of Cardiology, University Medical Center Mainz, Johannes Gutenberg-University Mainz, Germany (A.P.B.)
| |
Collapse
|
4
|
Goeldlin MB, Fandler-Höfler S, Pezzini A, Manikantan A, Rauch J, Hald SM, Kristensen ML, Obergottsberger L, Sembill JA, Haupenthal D, Larsen KT, Avramiotis NS, Polymeris AA, Periole C, Thiankhaw K, Rangus I, Puy L, Pasi M, Morotti A, Silvestrelli G, Giacalone G, Paciaroni M, Zedde M, Giorli E, Tassi R, Delgado-Romeu M, Fischer U, Volbers B, Hakim A, Z'Graggen WJ, Nolte CH, Werring DJ, Raposo N, Engelter ST, Kristoffersen ES, Kuramatsu J, Gattringer T, Gaist D, Seiffge DJ. Location and Timing of Recurrent, Nontraumatic Intracerebral Hemorrhage. JAMA Neurol 2025:2830856. [PMID: 40029641 DOI: 10.1001/jamaneurol.2025.0026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/05/2025]
Abstract
Importance : The spatial and temporal distribution of intracerebral hemorrhage (ICH) recurrence are largely unknown. Objective To assess timing and location of recurrent ICH events in relation to the index ICH event (adjacent ICH [adjICH] vs remote ICH [remICH]). Design, Setting, and Participants This cohort study was a pooled analysis of individual cohort studies from 2002 to 2021 among hospital-based European cohorts. Patients with 2 or more clinically distinguishable (≥1 recurrent) small vessel disease-related ICH events were included. Data analysis was performed from December 2023 to December 2024. Exposures ICH location and underlying small vessel disease type. Main Outcomes and Measures The primary outcome was adjICH, defined by anatomical ICH location and side, and the secondary outcome was time to recurrence. Multivariable regression analyses were conducted adjusting for ICH location, cerebral amyloid angiopathy according to Boston 2.0 or simplified Edinburgh criteria, convexity subarachnoid hemorrhage extension, hypertension, and antihypertensive treatment, including an interaction term for hypertension and antihypertensive treatment. Results Among 733 patients (median [IQR] age, 72.4 [65.2 to 79.0] years; 346 female [47.2%]), there were 1616 ICH events, including 733 index and 883 recurrent ICH events (range, 1 to 6 recurrences) over a median (IQR) follow-up of 2.53 (0.66 to 4.92) years. There were 340 patients (46.4%) with adjICH and 393 patients (53.6%) with remICH. Among recurrent ICH events, there were 476 adjICH events and 407 remICH events. In multivariable regression analyses, lobar index ICH (adjusted odds ratio [aOR], 2.08; 95% CI, 1.32 to 3.27) and cerebral amyloid angiopathy at index ICH (aOR, 2.21; 95% CI, 1.57 to 3.11) were associated with higher odds of adjICH, while cerebellar index ICH was associated with lower odds of adjICH (aOR, 0.25; 95% CI, 0.07 to 0.89). The median (IQR) time to recurrence was 1.25 (0.36 to 3.38) years for adjICH and 2.21 (0.66 to 4.85) years for remICH. Previous lobar or convexity subarachnoid hemorrhage (coefficient, -0.75; 95% CI, -1.25 to -0.25; P = .003 ), adjICH (coefficient, -0.60; 95% CI, -1.02 to -0.18; P = .005), and the number of previous ICH events (coefficient per 1-event increase, -0.62; 95% CI, -0.93 to -0.32; P < .001) were independently associated with a shorter time to recurrence. Conclusions and relevance This study found that early recurrence and cerebral amyloid angiopathy were associated with adjICH. These findings suggest that regional, tissue-based factors may facilitate recurrence and that identifying and targeting local vasculopathic changes may represent potential novel treatment targets.
Collapse
Affiliation(s)
- Martina B Goeldlin
- Department of Neurology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
| | - Simon Fandler-Höfler
- Department of Neurology, Medical University of Graz, Graz, Austria
- Stroke Research Centre, Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Alessandro Pezzini
- Department of Medicine and Surgery, University of Parma, Parma, Italy
- Stroke Care Program, Department of Emergency, Parma University Hospital, Parma, Italy
| | - Anusha Manikantan
- Department of Neurology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
| | - Janis Rauch
- Department of Neurology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
| | - Stine Munk Hald
- Research Unit for Neurology, Odense University Hospital and University of Southern Denmark, Odense, Denmark
| | - Mona Løgtholt Kristensen
- Department of Radiology, Odense University Hospital and University of Southern Denmark, Odense, Denmark
| | | | | | | | | | - Nikolaos S Avramiotis
- Department of Clinical Research and Department of Neurology, University Hospital and University of Basel, Basel, Switzerland
| | - Alexandros A Polymeris
- Department of Clinical Research and Department of Neurology, University Hospital and University of Basel, Basel, Switzerland
| | - Charlotte Periole
- Department of Neurology, Hôpital Pierre-Paul Riquet, CHU Toulouse, Toulouse, France
| | - Kitti Thiankhaw
- Stroke Research Centre, Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Ida Rangus
- Department of Neurology with experimental Neurology, Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Laurent Puy
- University Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Lille, France
| | - Marco Pasi
- Department of Neurology, University Hospital of Tours, Inserm U1253, CIC-IT 1245, Tours, France
| | | | | | - Giacomo Giacalone
- Neurology Unit and Stroke Unit, IRCCS S. Raffaele Hospital, Milano, Italy
| | - Maurizio Paciaroni
- Department of Neurosciences and Rehabilitation, Azienda Ospedaliero-Universitaria di Ferrara, Italy
| | - Marialuisa Zedde
- Neurology and Stroke Unit, AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy
| | - Elisa Giorli
- Neurology Unit, S. Andrea Hospital, La Spezia, Italy
| | | | - Marc Delgado-Romeu
- Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Urs Fischer
- Department of Neurology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
| | - Bastian Volbers
- Department of Neurology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
| | - Arsany Hakim
- Institute of Diagnostic and Interventional Neuroradiology, Stroke Research Center Bern, Inselspital, Bern University Hospital, University of Bern, Switzerland
| | - Werner J Z'Graggen
- Department of Neurology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
- Department of Neurosurgery, Inselspital University Hospital and University of Bern, Switzerland
| | - Christian H Nolte
- Department of Neurology with experimental Neurology, Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany
- Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - David J Werring
- Stroke Research Centre, Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Nicolas Raposo
- Department of Neurology, Hôpital Pierre-Paul Riquet, CHU Toulouse, Toulouse, France
- NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France
| | - Stefan T Engelter
- Department of Clinical Research and Department of Neurology, University Hospital and University of Basel, Basel, Switzerland
- Neurology and Neurorehabilitation, University Department of Geriatric Medicine Felix Platter, University Hospital and University of Basel, Basel, Switzerland
| | | | - Joji Kuramatsu
- Department of Neurology, University Hospital Erlangen, Germany
- Department of Neurology, RoMed Klinikum, Rosenheim, Germany
| | | | - David Gaist
- Research Unit for Neurology, Odense University Hospital and University of Southern Denmark, Odense, Denmark
| | - David J Seiffge
- Department of Neurology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
| |
Collapse
|
5
|
Snorradottir AO, Hakonarson H, Palsdottir A. The historical background of hereditary cystatin C amyloid angiopathy: Genealogical, pathological, and clinical manifestations. Brain Pathol 2025; 35:e13291. [PMID: 39054254 PMCID: PMC11835439 DOI: 10.1111/bpa.13291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2024] [Accepted: 07/05/2024] [Indexed: 07/27/2024] Open
Abstract
Hereditary cystatin C amyloid angiopathy (HCCAA) is an Icelandic disease that belongs to a disease class called cerebral amyloid angiopathy, a group of heterogenous diseases presenting with aggregation of amyloid complexes and deposition predominantly in the central nervous system. HCCAA is dominantly inherited, caused by L68Q mutation in the cystatin C gene, leading to aggregation of the cystatin C protein. HCCAA is a very progressive and severe disease, with widespread cerebral and parenchymal cystatin C and collagen IV deposition within the central nervous system (CNS) but also in other organs in the body, for example, in the skin. Most L68Q carriers have clinical symptoms characterized by recurrent hemorrhages and dementia, between the age of 20-30 years. If the carriers survive the first hemorrhage, the frequency and severity of the hemorrhages tend to increase, resulting in death at average of 30 years with mean number of major hemorrhages ranging from 3.2 to 3.9 over a 5-year average life span. The pathogenesis of the disease in carriers is very similar in the CNS and in the skin based on autopsy studies, thus skin biopsies can be used to monitor the progression of the disease by quantifying the cystatin C immunoreactivity. The cystatin C deposition always colocalizes with collagen IV and fibroblasts in the skin are found to be the main cell type responsible for the deposition of both proteins. No therapy is available for this devastating disease.
Collapse
Affiliation(s)
- Asbjorg Osk Snorradottir
- Faculty of MedicineUniversity of IcelandReykjavikIceland
- Department of PathologyLandspitali University HospitalReykjavikIceland
| | - Hakon Hakonarson
- Faculty of MedicineUniversity of IcelandReykjavikIceland
- Center for Applied Genomics, Division of Human GeneticsThe Children's Hospital of PhiladelphiaPhiladelphiaPennsylvaniaUSA
- Department of PediatricsThe Perelman School of Medicine, University of PennsylvaniaPhiladelphiaPennsylvaniaUSA
| | | |
Collapse
|
6
|
Muir RT, Stukas S, Cooper JG, Beaudin AE, McCreary CR, Gee M, Nelles K, Nukala N, Valencia J, Kirmess KM, Black SE, Hill MD, Camicioli R, Wellington CL, Smith EE. Plasma biomarkers distinguish Boston Criteria 2.0 cerebral amyloid angiopathy from healthy controls. Alzheimers Dement 2025; 21:e70010. [PMID: 40156276 PMCID: PMC11953569 DOI: 10.1002/alz.70010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2024] [Revised: 12/15/2024] [Accepted: 01/23/2025] [Indexed: 04/01/2025]
Abstract
INTRODUCTION Cerebral amyloid angiopathy (CAA) is characterized by the deposition of beta-amyloid (Aβ) in small vessels leading to hemorrhagic stroke and dementia. This study examined whether plasma Aβ42/40, phosphorylated-tau (p-tau), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) differ in CAA and their potential to discriminate Boston Criteria 2.0 probable CAA from healthy controls. METHODS Plasma Aβ42/40, p-tau-181, NfL, and GFAP were quantified using single molecule array (Simoa) and Aβ42/40 was also independently quantified using immunoprecipitation liquid chromatography mass-spectrometry (IPMS). RESULTS Forty-five participants with CAA and 47 healthy controls had available plasma. Aβ42/40 ratios were significantly lower in CAA than healthy controls. While p-tau-181 and NfL were elevated in CAA, GFAP was similar. A combination of Aβ42/40 (Simoa), p-tau-181, and NfL resulted in an area under the curve of 0.90 (95% confidence interval: 0.80, 0.95). DISCUSSION Plasma Aβ42/40, p-tau-181, and NfL differ in those with CAA and together can discriminate CAA from healthy controls. HIGHLIGHTS Participants with CAA had reduced plasma Aβ42/40 ratios compared to controls. Plasma p-tau-181 and NfL concentrations are elevated in CAA compared to controls. Plasma GFAP was similar in CAA and controls. Together, plasma Aβ42/40, p-tau-181, and NfL had excellent discriminability for CAA.
Collapse
Affiliation(s)
- Ryan T. Muir
- Calgary Stroke ProgramUniversity of CalgaryCalgaryAlbertaCanada
- Hotchkiss Brain Institute, Departments of RadiologyUniversity of CalgaryCalgaryAlbertaCanada
- Community Health Sciences, Departments of RadiologyUniversity of CalgaryCalgaryAlbertaCanada
- Clinical NeurosciencesUniversity of CalgaryCalgaryAlbertaCanada
- L.C Campbell Cognitive Neurology Research Unit, Dr Sandra Black Centre for Brain Resilience and Recovery, and Hurvitz Brain Sciences Program, Sunnybrook Research InstituteUniversity of TorontoNorth YorkOntarioCanada
| | - Sophie Stukas
- Department of Pathology and Laboratory Medicine, Djavad Mowafaghian Centre for Brain HealthUniversity of British ColumbiaVancouverBritish ColumbiaCanada
| | - Jennifer G. Cooper
- Department of Pathology and Laboratory Medicine, Djavad Mowafaghian Centre for Brain HealthUniversity of British ColumbiaVancouverBritish ColumbiaCanada
| | - Andrew E. Beaudin
- Hotchkiss Brain Institute, Departments of RadiologyUniversity of CalgaryCalgaryAlbertaCanada
- Clinical NeurosciencesUniversity of CalgaryCalgaryAlbertaCanada
| | - Cheryl R. McCreary
- Hotchkiss Brain Institute, Departments of RadiologyUniversity of CalgaryCalgaryAlbertaCanada
- Clinical NeurosciencesUniversity of CalgaryCalgaryAlbertaCanada
- Departments of RadiologyUniversity of CalgaryCalgaryAlbertaCanada
| | - Myrlene Gee
- Division of Neurology, Department of MedicineUniversity of AlbertaEdmontonAlbertaCanada
| | - Krista Nelles
- Division of Neurology, Department of MedicineUniversity of AlbertaEdmontonAlbertaCanada
| | - Nikita Nukala
- Clinical NeurosciencesUniversity of CalgaryCalgaryAlbertaCanada
| | - Janina Valencia
- Clinical NeurosciencesUniversity of CalgaryCalgaryAlbertaCanada
| | | | - Sandra E. Black
- L.C Campbell Cognitive Neurology Research Unit, Dr Sandra Black Centre for Brain Resilience and Recovery, and Hurvitz Brain Sciences Program, Sunnybrook Research InstituteUniversity of TorontoNorth YorkOntarioCanada
| | - Michael D. Hill
- Calgary Stroke ProgramUniversity of CalgaryCalgaryAlbertaCanada
- Hotchkiss Brain Institute, Departments of RadiologyUniversity of CalgaryCalgaryAlbertaCanada
- Community Health Sciences, Departments of RadiologyUniversity of CalgaryCalgaryAlbertaCanada
| | - Richard Camicioli
- Division of Neurology, Department of MedicineUniversity of AlbertaEdmontonAlbertaCanada
- Neuroscience and Mental Health InstituteUniversity of AlbertaEdmontonAlbertaCanada
| | - Cheryl L. Wellington
- Department of Pathology and Laboratory Medicine, Djavad Mowafaghian Centre for Brain HealthUniversity of British ColumbiaVancouverBritish ColumbiaCanada
| | - Eric E. Smith
- Calgary Stroke ProgramUniversity of CalgaryCalgaryAlbertaCanada
- Hotchkiss Brain Institute, Departments of RadiologyUniversity of CalgaryCalgaryAlbertaCanada
- Community Health Sciences, Departments of RadiologyUniversity of CalgaryCalgaryAlbertaCanada
- Clinical NeurosciencesUniversity of CalgaryCalgaryAlbertaCanada
| |
Collapse
|
7
|
Liao TW, Lai TS, Wu CH. The Impact of Autosomal Dominant Polycystic Kidney Disease on the Presence of Cerebral Microbleeds: A Case-Control Matched Study. Acad Radiol 2025:S1076-6332(24)01033-X. [PMID: 39880693 DOI: 10.1016/j.acra.2024.12.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2024] [Revised: 12/06/2024] [Accepted: 12/19/2024] [Indexed: 01/31/2025]
Abstract
RATIONALE AND OBJECTIVES Individuals with autosomal dominant polycystic kidney disease (ADPKD) can present with diverse renal and extra-renal manifestations. Large vessel anomalies, such as cerebral aneurysms, are potentially fatal extra-renal manifestations. However, limited research has been conducted on cerebral small vessel disease (CSVD). This study aimed to examine the correlation between ADPKD and CSVD, specifically cerebral microbleeds (CMs) and white matter hyperintensity (WMH). MATERIALS AND METHODS This retrospective study with a prospective design included 140 participants aged >20 years diagnosed with ADPKD between 2014 and 2023. The reference cohort included 126 outpatients without ADPKD within the same period. After 1:1 matching for sex, age, chronic kidney disease (CKD) stage, and hypertension (HTN) status during the same period, 45 pairs of patients were enrolled. Cerebral magnetic resonance imaging was reviewed for qualitative and quantitative analyses of CMs and WMH. RESULTS There were significant differences between the ADPKD and non-ADPKD groups in the presence of cerebral (p=0.036) and deep microbleeds (p=0.003). Univariate and multivariable analysis revealed that ADPKD (odds ratio [OR]: 6.18, 95% confidence interval [CI]: 1.26-30.40, p=0.025) and age (OR: 1.10, 95% CI: 1.04-1.18, p=0.003) were independently associated with CMs. In contrast, age (OR: 1.19, 95% CI: 1.05-1.34, p=0.006) was independently associated with moderate-to-severe WMH, while ADPKD was not. CONCLUSION Individuals diagnosed with ADPKD exhibited markedly elevated susceptibility to CMs compared to non-ADPKD participants after adjusting for age, sex, HTN, and CKD stage.
Collapse
Affiliation(s)
- Ting-Wei Liao
- Department of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan (T.W.L., C.H.W.)
| | - Tai-Shuan Lai
- Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan (T.S.L.)
| | - Chih-Horng Wu
- Department of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan (T.W.L., C.H.W.); Center of Minimal-Invasive Interventional Radiology, National Taiwan University Hospital, Taipei, Taiwan (C.H.W.); Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan (C.H.W.).
| |
Collapse
|
8
|
Das AS, Abramovitz Fouks A, Gökçal E, Rotschild O, Pasi M, Regenhardt RW, Goldstein JN, Viswanathan A, Rosand J, Greenberg SM, Gurol ME. Characterizing the underlying microangiopathy of deep cerebellar intracerebral hemorrhage. J Neurol 2025; 272:167. [PMID: 39853492 DOI: 10.1007/s00415-025-12905-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2024] [Revised: 01/03/2025] [Accepted: 01/06/2025] [Indexed: 01/26/2025]
Abstract
INTRODUCTION While cerebral amyloid angiopathy is likely responsible for intracerebral hemorrhage (ICH) occurring in superficial (grey matter, vermis) cerebellar locations, it is unclear whether hypertensive arteriopathy (HA), the other major cerebral small vessel disease (cSVD), is associated with cerebellar ICH (cICH) in deep (white matter, deep nuclei, cerebellar peduncle) regions. We tested the hypothesis that HA-associated neuroimaging markers are significantly associated with deep cICH compared to superficial cICH. PATIENTS AND METHODS Brain MRI scans from consecutive non-traumatic cICH patients admitted to a referral center were analyzed for cSVD markers. Clinical risk factors, left ventricular hypertrophy (LVH, a marker of hypertensive end-organ damage), and neuroimaging markers were compared between patients with deep and superficial cICH in univariate and multivariable models. RESULTS Hypertension and LVH were more common among 83 (64%) patients with deep cICH compared to 46 (36%) with superficial cICH. HA-related markers such as peri-basal ganglia white matter hyperintensity pattern, deep lacunes, severe basal ganglia enlarged perivascular spaces, and deep cerebral microbleeds (CMBs) were more common among those with deep vs. superficial cICH. Strictly lobar CMBs were less common among patients with deep cICH, whereas mixed-location CMBs were more common. After multivariable adjustment, LVH (aOR 4.06, 95% CI [1.22-13.50], p = 0.02), deep lacunes (aOR 6.02, 95% CI [1.46-24.89], p = 0.01), and strictly lobar CMBs (aOR 0.09, 95% CI [0.02-0.45], p < 0.01) remained significantly associated with deep cICH. DISCUSSION AND CONCLUSION Because HA-associated markers are significantly associated with deep cICH, it is likely HA is the dominant underlying microangiopathy of this ICH subtype.
Collapse
Affiliation(s)
- Alvin S Das
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
- Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Lowry Medical Office Building, Ste 9A-05, Boston, MA, 02215, USA.
| | - Avia Abramovitz Fouks
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Elif Gökçal
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Ofer Rotschild
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Marco Pasi
- Centre Hospitalier, Université de Tours, Tours, France
| | - Robert W Regenhardt
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Joshua N Goldstein
- Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Anand Viswanathan
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Jonathan Rosand
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- Henry and Allison McCance Center for Brain Health, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Steven M Greenberg
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - M Edip Gurol
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
9
|
Zhang M, Che R, Liu X, Hou C, Wang Z, Hu S, Fu S, Kan Y, Sun H, Xu J, Ma S, Li S, Ren C, Zhao W, Jia M, Wang J, Wu C, Ji X. Clinical diagnosis of cerebral amyloid angiopathy related hemorrhage in China: Simplified Edinburgh criteria and Boston criteria version 2.0. Eur Stroke J 2025:23969873241309513. [PMID: 39827411 PMCID: PMC11744617 DOI: 10.1177/23969873241309513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2024] [Accepted: 12/09/2024] [Indexed: 01/22/2025] Open
Abstract
BACKGROUND Accurate diagnosis of cerebral amyloid angiopathy (CAA) in surviving patients is indispensable for making treatment decisions and conducting clinical trials. We aimed to evaluate the diagnostic value and clinical utility of the simplified Edinburgh computed tomography (CT) criteria for CAA-related hemorrhage in Chinese patients. METHODS We analyzed 212 patients with lobar hemorrhage who underwent brain CT and magnetic resonance imaging (MRI) from a multicentre cohort. Using the Boston criteria version 2.0 (v2.0) as the gold standard, we assessed the application value of the simplified Edinburgh CT criteria, and investigated whether the Edinburgh CT criteria predict patient outcomes. RESULTS Patients with probable CAA accounted for 36.6% according to the Boston criteria v2.0. The Edinburgh CT criteria indicated an area under the receiver operating characteristic curves (AUC) of 0.735 for the diagnosis of probable CAA, and it performed better when there was a high-risk threshold of CAA in the decision curve analysis. Patients with a high risk of CAA based on the Edinburgh CT criteria had poorer outcomes at 90-day after adjusting for confounding factors (p = 0.034). Finger-like projections in the Edinburgh CT criteria were associated with lobar microbleeds, cortical superficial siderosis, and multispot white matter hyperintensity according to the Boston criteria. CONCLUSIONS Taking the Boston criteria v2.0 as the gold standard, the Edinburgh CT criteria demonstrated good diagnostic value and predicted outcomes well at 90-day in Chinese patients with lobar hemorrhage. Further studies with larger sample sizes are required to confirm these findings.
Collapse
Affiliation(s)
- Mengke Zhang
- Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
| | - Ruiwen Che
- Department of Neurology, Beijing ShiJiTan hospital, Capital Medical University, Beijing, China
| | - Xin Liu
- Department of Radiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
| | - Chengbei Hou
- Center for Evidence-Based Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
| | - Zhongyue Wang
- Department of Neurology, Henan Province People’s Hospital, Henan, China
| | - Sen Hu
- Department of Medical Records, Henan Province People’s Hospital, Henan, China
| | - Shengqi Fu
- Department of Neurology, People’s Hospital of Zhengzhou, Henan, China
| | - Yuan Kan
- Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
| | - Hailiang Sun
- Department of Neurosurgery, Beijing Fengtai You`anmen Hospital, Beijing, China
| | - Jianmin Xu
- Department of Radiology, Beijing Fengtai You`anmen Hospital, Beijing, China
| | - Shiliang Ma
- Department of Radiology, Beijing Fengtai You`anmen Hospital, Beijing, China
| | - Sijie Li
- Emergency Department, Xuanwu Hospital, Capital Medical University, Beijing, China
| | - Changhong Ren
- Beijing Key Laboratory of Hypoxia Conditioning Translational Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
| | - Wenbo Zhao
- Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
| | - Milan Jia
- Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
| | - Jingang Wang
- Department of Radiology, Beijing Fengtai You`anmen Hospital, Beijing, China
| | - Chuanjie Wu
- Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
| | - Xunming Ji
- Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China
- Beijing Institute of Brain Disorders, Capital Medical University, Beijing, China
| |
Collapse
|
10
|
Reynolds B, McLaine R. An older man with progressive short-term memory loss and confusion. JAAPA 2025; 38:e5-e8. [PMID: 39699323 DOI: 10.1097/01.jaa.0000000000000151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2024]
Abstract
ABSTRACT A 72-year-old man with progressive memory loss and confusion presented to a neurology clinic for evaluation. He initially had difficulty remembering names and misplaced objects; however, his memory deficits had progressed, and more recently he had numerous car accidents and difficulty managing his own medications and finances. Cognitive testing revealed significant memory deficits reflecting moderate-stage dementia, and his brain MRI showed several cortical microbleeds and an area of siderosis consistent with the diagnosis of cerebral amyloid angiopathy (CAA). This case report provides an overview of a classic case of CAA and its potential treatment options.
Collapse
Affiliation(s)
- Beverly Reynolds
- Beverly Reynolds practices at the VA Boston Healthcare System in West Roxbury, Mass. Rosalind McLaine is director of clinical operations at Alzheon, Inc., in Framingham, Mass. The authors have disclosed no potential conflicts of interest, financial or otherwise
| | | |
Collapse
|
11
|
Tanaka F, Maeda M, Kishi S, Kogue R, Umino M, Ishikawa H, Ii Y, Shindo A, Sakuma H. Updated imaging markers in cerebral amyloid angiopathy: What radiologists need to know. Jpn J Radiol 2024:10.1007/s11604-024-01720-2. [PMID: 39730931 DOI: 10.1007/s11604-024-01720-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2024] [Accepted: 12/06/2024] [Indexed: 12/29/2024]
Abstract
Cerebral amyloid angiopathy (CAA) is an age-related small vessel disease pathologically characterized by the progressive accumulation of amyloid-beta (Aβ) peptide in cerebrovascular walls, affecting both cortical and leptomeningeal vessels. Amyloid deposition results in fragile vessels, which may lead to lobar intracerebral hemorrhage (ICH) and cognitive impairment. To evaluate the probability and severity of CAA, the imaging markers depicted on CT and MRI techniques are crucial, as brain pathological examination is highly invasive. Although the Boston criteria have established diagnostic value and have been updated to version 2.0, due to an aging population, the patients with CAA should also be assessed for their risk of future ICH or cognitive impairment. Furthermore, an increased awareness of CAA is essential when introducing anticoagulants for infarct in elderly patients or anti-amyloid antibodies for Alzheimer's disease, as these may worsen CAA-related hemorrhagic lesions. However, the radiological literature on CAA has not been comprehensively updated. Here, we review the imaging markers of CAA and clinical significance. We also discuss the clinical and imaging characteristics of CAA-related inflammation, amyloid-related imaging abnormalities, and iatrogenic-CAA.
Collapse
Affiliation(s)
- Fumine Tanaka
- Department of Radiology, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu, Mie, 514-8507, Japan.
| | - Masayuki Maeda
- Department of Neuroradiology, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu, Mie, 514-8507, Japan
| | - Seiya Kishi
- Department of Radiology, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu, Mie, 514-8507, Japan
| | - Ryota Kogue
- Department of Radiology, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu, Mie, 514-8507, Japan
| | - Maki Umino
- Department of Radiology, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu, Mie, 514-8507, Japan
| | - Hidehiro Ishikawa
- Department of Neurology, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu, Mie, 514-8507, Japan
| | - Yuichiro Ii
- Department of Neuroimaging and Pathophysiology, Mie University School of Medicine, 2-174, Edobashi, Tsu, Mie, 514-8507, Japan
| | - Akihiro Shindo
- Department of Neurology, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu, Mie, 514-8507, Japan
| | - Hajime Sakuma
- Department of Radiology, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu, Mie, 514-8507, Japan
| |
Collapse
|
12
|
Tsuchida A, Goubet M, Boutinaud P, Astafeva I, Nozais V, Hervé PY, Tourdias T, Debette S, Joliot M. SHIVA-CMB: a deep-learning-based robust cerebral microbleed segmentation tool trained on multi-source T2*GRE- and susceptibility-weighted MRI. Sci Rep 2024; 14:30901. [PMID: 39730628 DOI: 10.1038/s41598-024-81870-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2024] [Accepted: 11/29/2024] [Indexed: 12/29/2024] Open
Abstract
Cerebral microbleeds (CMB) represent a feature of cerebral small vessel disease (cSVD), a prominent vascular contributor to age-related cognitive decline, dementia, and stroke. They are visible as spherical hypointense signals on T2*- or susceptibility-weighted magnetic resonance imaging (MRI) sequences. An increasing number of automated CMB detection methods being proposed are based on supervised deep learning (DL). Yet, the lack of open sharing of pre-trained models hampers the practical application and evaluation of these methods beyond specific data sources used in each study. Here, we present the SHIVA-CMB detector, a 3D Unet-based tool trained on 450 scans taken from seven acquisitions in six different cohort studies that included both T2*- and susceptibility-weighted MRI. In a held-out test set of 96 scans, it achieved the sensitivity, precision, and F1 (or Dice similarity coefficient) score of 0.67, 0.82, and 0.74, with less than one false positive detection per image (FPavg = 0.6) and per CMB (FPcmb = 0.15). It achieved a similar level of performance in a separate, evaluation-only dataset with acquisitions never seen during the training (0.67, 0.91, 0.77, 0.5, 0.07 for the sensitivity, precision, F1 score, FPavg, and FPcmb). Further demonstrating its generalizability, it showed a high correlation (Pearson's R = 0.89, p < 0.0001) with a visual count by expert raters in another independent set of 1992 T2*-weighted scans from a large, multi-center cohort study. Importantly, we publicly share both the pipeline ( https://github.com/pboutinaud/SHiVAi/ ) and pre-trained models ( https://github.com/pboutinaud/SHIVA-CMB/ ) to the research community to promote the active application and evaluation of our tool. We believe this effort will help accelerate research on the pathophysiology and functional consequences of CMB by enabling rapid characterization of CMB in large-scale studies.
Collapse
Affiliation(s)
- Ami Tsuchida
- GIN, IMN-UMR5293, CEA, CNRS, Université de Bordeaux, Bordeaux, France
- BPH-U1219, INSERM, Université de Bordeaux, Bordeaux, France
| | | | | | - Iana Astafeva
- GIN, IMN-UMR5293, CEA, CNRS, Université de Bordeaux, Bordeaux, France
- BPH-U1219, INSERM, Université de Bordeaux, Bordeaux, France
| | | | | | - Thomas Tourdias
- Neuroimagerie diagnostique et thérapeutique, CHU de Bordeaux, Bordeaux, France
- Neurocentre Magendie-U1219, INSERM, Université de Bordeaux, Bordeaux, France
| | | | - Marc Joliot
- GIN, IMN-UMR5293, CEA, CNRS, Université de Bordeaux, Bordeaux, France.
| |
Collapse
|
13
|
Grund B, Ebert A, Sandikci V, Neumaier-Probst E, Alonso A. Benefits of early MR-Imaging in patients with acute spontaneous intracerebral hemorrhage: a retrospective study. BMC Neurol 2024; 24:487. [PMID: 39707219 DOI: 10.1186/s12883-024-03992-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2024] [Accepted: 12/10/2024] [Indexed: 12/23/2024] Open
Abstract
BACKGROUND Neuroimaging plays a vital role in the diagnosis of intracerebral hemorrhage (ICH) and in identifying the underlying etiology for appropriate therapeutic approach. This study aims to determine the significance and potential advantages of using early magnetic resonance imaging (MRI) as a diagnostic tool for ICH. METHODS This retrospective study included 359 patients with ICH treated at the Department of Neurology, Mannheim University Hospital between January 2017 and December 2021. Patient characteristics, stroke severity and imaging procedures were descriptively analyzed. Factors associated with the choice of imaging modalities were evaluated. The etiology of hemorrhage was retrospectively analyzed using the existing data. We recorded the reassignment of ICH etiology by comparing the assessment after first sole review of CT scan and then subsequent MRI review. The overall rate of reassignments and the reassignments per CT-based initial etiology were analyzed. RESULTS In the sample of 359 patients with ICH (mean age 73.1 years, 55.4% male), patients receiving an additional MRI were significantly younger (p < .001) and were less severely affected by stroke (median NIHSS score 5 vs. 15, p < .001). MRI was performed significantly less frequently in patients who died during hospitalization (11.7% vs. 63.9%, p < .001). MRI led to a reassignment of ICH etiology in 48.2% of cases (80/166), uncovering unknown underlying causes in 69% of cases (49/71). Reassignment occurred most frequently in patients with a CT-based diagnosis of hypertensive ICH (18/50). The most frequent reassigned etiologies after MR imaging were cerebral amyloid angiopathy (CAA; 36 patients) and secondary hemorrhage of an ischemic stroke (30 patients). CONCLUSIONS Early MR imaging in patients with ICH improves the determination of underlying etiology and the conception of an appropriate treatment approach, potentially contributing to better patient outcomes.
Collapse
Affiliation(s)
- Benedikt Grund
- Department of Neurology, Mannheim Center for Translational Neuroscience, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, Mannheim, 68167, Germany
| | - Anne Ebert
- Department of Neurology, Mannheim Center for Translational Neuroscience, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, Mannheim, 68167, Germany
| | - Vesile Sandikci
- Department of Neurology, Mannheim Center for Translational Neuroscience, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, Mannheim, 68167, Germany
| | - Eva Neumaier-Probst
- Department of Neuroradiology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Angelika Alonso
- Department of Neurology, Mannheim Center for Translational Neuroscience, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, Mannheim, 68167, Germany.
| |
Collapse
|
14
|
Thiankhaw K, Best J, Srivastava S, Prachee I, Agarwal S, Tan S, Calvert PA, Chughtai A, Ang R, Segal OR, Werring DJ. Left atrial appendage occlusion in patients with atrial fibrillation and intracerebral haemorrhage associated with cerebral amyloid angiopathy: a multicentre observational study and pooled analysis of published studies. J Neurol Neurosurg Psychiatry 2024:jnnp-2024-334718. [PMID: 39694822 DOI: 10.1136/jnnp-2024-334718] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/29/2024] [Accepted: 11/20/2024] [Indexed: 12/20/2024]
Abstract
BACKGROUND Cerebral amyloid angiopathy (CAA) is a common cause of intracerebral haemorrhage (ICH) with a high recurrence risk. Left atrial appendage occlusion (LAAO) is a method for ischaemic stroke prevention in patients with atrial fibrillation (AF), potentially reducing the risk of intracranial bleeding in CAA-associated ICH. We aimed to determine the outcomes of patients with AF with CAA-associated ICH undergoing LAAO. METHODS We conducted a multicentre study of patients with CAA-associated ICH who underwent LAAO for stroke prevention. We pooled our findings with data from a systematic review of relevant published studies of LAAO for AF in ICH survivors reporting CAA diagnosis. RESULTS We included data from two published studies (n=65) with CAA-specific data and our cohort study (n=37), providing a total of 102 participants (mean age 76.2±8.0 years, 74.6% male) with CAA-related symptomatic ICH and AF treated with LAAO. The median follow-up period was 9.4 months (IQR 4.2-20.6). Postprocedural antithrombotic regimens varied between single (73.0%) or dual antiplatelet therapy (16.2%), or direct oral anticoagulant (DOAC) (10.8%), with a median duration of 42 days (IQR 35-74). Postprocedural complications were uncommon, but included transient arrhythmias (2.1%) and non-life-threatening tamponade (2.1%). Pooled incidence rates of ischaemic stroke and ICH during follow-up were 5.16 (95% CI 1.36 to 17.48) and 2.73 (95% CI 0.41 to 13.94) per 100 patient years, respectively. CONCLUSIONS LAAO followed by short-term antithrombotic therapy might be a safe and effective ischaemic stroke preventive strategy in people with CAA-associated ICH and AF. However, randomised controlled trials are needed to determine how LAAO compares with long-term DOAC in this population. PROSPERO REGISTRATION NUMBER CRD42023415354.
Collapse
Affiliation(s)
- Kitti Thiankhaw
- Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, London, UK
- Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand
| | - Jonathan Best
- Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, London, UK
| | - Sonal Srivastava
- Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, London, UK
| | - Ishika Prachee
- Department of Cardiac Electrophysiology, Saint Bartholomew's Hospital Barts Heart Centre, London, UK
| | - Smriti Agarwal
- Department of Stroke Medicine, Clinical Neurosciences, Addenbrooke's Hospital, Cambridge, UK
| | - Serena Tan
- Department of Stroke Medicine, Clinical Neurosciences, Addenbrooke's Hospital, Cambridge, UK
| | - Patrick A Calvert
- Department of Cardiology, Royal Papworth Hospital, Cambridge, UK
- University of Cambridge, Cambridge, UK
| | - Asim Chughtai
- Department of Cardiology, Royal Papworth Hospital, Cambridge, UK
| | - Richard Ang
- Department of Cardiac Electrophysiology, Saint Bartholomew's Hospital Barts Heart Centre, London, UK
| | - Oliver R Segal
- Department of Cardiac Electrophysiology, Saint Bartholomew's Hospital Barts Heart Centre, London, UK
| | - David J Werring
- Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, London, UK
| |
Collapse
|
15
|
Seiffge DJ, Fandler-Höfler S, Du Y, Goeldlin MB, Jolink WMT, Klijn CJM, Werring DJ. Intracerebral haemorrhage - mechanisms, diagnosis and prospects for treatment and prevention. Nat Rev Neurol 2024; 20:708-723. [PMID: 39548285 DOI: 10.1038/s41582-024-01035-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/11/2024] [Indexed: 11/17/2024]
Abstract
Intracerebral haemorrhage (ICH) is a devastating condition associated with high mortality and substantial residual disability among survivors. Effective treatments for the acute stages of ICH are limited. However, promising findings from randomized trials of therapeutic strategies, including acute care bundles that target anticoagulation therapies, blood pressure control and other physiological parameters, and trials of minimally invasive neurosurgical procedures have led to renewed optimism that patient outcomes can be improved. Currently ongoing areas of research for acute treatment include anti-inflammatory and haemostatic treatments. The implementation of effective secondary prevention strategies requires an understanding of the aetiology of ICH, which involves vascular and brain parenchymal imaging; the use of neuroimaging markers of cerebral small vessel disease improves classification with prognostic relevance. Other data underline the importance of preventing not only recurrent ICH but also ischaemic stroke and cardiovascular events in survivors of ICH. Ongoing and planned randomized controlled trials will assess the efficacy of prevention strategies, including antiplatelet agents, oral anticoagulants or left atrial appendage occlusion (in patients with concomitant atrial fibrillation), and optimal management of long-term blood pressure and statin use. Together, these advances herald a new era of improved understanding and effective interventions to reduce the burden of ICH.
Collapse
Affiliation(s)
- David J Seiffge
- Department of Neurology, Inselspital University Hospital Bern and University of Bern, Bern, Switzerland
| | - Simon Fandler-Höfler
- Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, University College London, London, UK
- Department of Neurology, Medical University of Graz, Graz, Austria
| | - Yang Du
- Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, University College London, London, UK
- Department of Neurology, Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Martina B Goeldlin
- Department of Neurology, Inselspital University Hospital Bern and University of Bern, Bern, Switzerland
| | | | - Catharina J M Klijn
- Department of Neurology, Donders Institute of Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, Netherlands
| | - David J Werring
- Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, University College London, London, UK.
| |
Collapse
|
16
|
Sousa L, Pinto C, Azevedo A, Igreja L, Marta A, Fernandes J, Oliveira P, Cardoso M, Alves C, Silva AMD, Mendonça Pinto M, Sousa AP, Coelho T, Taipa R. Brain MRI in patients with V30M hereditary transthyretin amyloidosis. Amyloid 2024; 31:285-290. [PMID: 39153196 DOI: 10.1080/13506129.2024.2391842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/19/2024] [Revised: 07/27/2024] [Accepted: 08/08/2024] [Indexed: 08/19/2024]
Abstract
BACKGROUND Central nervous system dysfunction is common in longstanding hereditary transthyretin amyloidosis (ATTRv) caused by the V30M (p.V50M) mutation. Neuropathology studies show leptomeningeal amyloid deposition and cerebral amyloid angiopathy (CAA). Brain MRI is widely used in the assessment of Aβ associated CAA but there are no systematic studies with brain MRI in ATTRv amyloidosis. METHODS we performed 3 T brain MRIs in 16 patients with longstanding (>14 years) ATTRV30M. We additionally retrospectively reviewed 48 brain MRIs from patients followed at our clinic. CNS symptoms and signs were systematically accessed, and MRIs were blindly reviewed for ischaemic and haemorrhagic lesions. RESULTS in the prospective cohort, we found white matter hyperintensities in 8/16 patients (50%, Fazekas score> =1). There were no relevant microbleeds, large ischaemic or haemorrhagic lesions or superficial siderosis. In the retrospective cohort, microbleeds were found in 5/48 patients (10,4%), two of which with > =20 microbleeds. White matter hyperintensities were found in 20/48 cases (41.7%). White matter lesions, microbleeds and cortical atrophy were not associated with disease duration. CONCLUSIONS white matter hyperintensities are common in ATTRV30M, irrespective of disease duration. Haemorrhagic lesions are rare, even in patients with longstanding disease, suggesting the existence of other risk factors.
Collapse
Affiliation(s)
- Luísa Sousa
- Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal
- Unidade Corino de Andrade, Centro Hospitalar Universitário de Santo António, Porto, Portugal
- Neurology Department, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal
| | - Catarina Pinto
- Neuroradiology Department, Centro Hospitalar Universitário de Santo António, Porto, Portugal
| | - Ana Azevedo
- Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal
- Neurology Department, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal
| | - Liliana Igreja
- Neuroradiology Department, Centro Hospitalar Universitário de Santo António, Porto, Portugal
| | - Ana Marta
- Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal
- Ophthalmology Department, Centro Hospitalar Universitário de Santo António, Porto, Portugal
| | - Joana Fernandes
- Unidade Corino de Andrade, Centro Hospitalar Universitário de Santo António, Porto, Portugal
| | - Pedro Oliveira
- Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal
| | - Márcio Cardoso
- Unidade Corino de Andrade, Centro Hospitalar Universitário de Santo António, Porto, Portugal
| | - Cristina Alves
- Unidade Corino de Andrade, Centro Hospitalar Universitário de Santo António, Porto, Portugal
| | - Ana Martins da Silva
- Unidade Corino de Andrade, Centro Hospitalar Universitário de Santo António, Porto, Portugal
| | - Miguel Mendonça Pinto
- Unidade Corino de Andrade, Centro Hospitalar Universitário de Santo António, Porto, Portugal
- Portuguese Brain Bank, Centro Hospitalar Universitário de Santo António, Porto, Portugal
| | - Ana Paula Sousa
- Unidade Corino de Andrade, Centro Hospitalar Universitário de Santo António, Porto, Portugal
| | - Teresa Coelho
- Unidade Corino de Andrade, Centro Hospitalar Universitário de Santo António, Porto, Portugal
| | - Ricardo Taipa
- Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal
- Portuguese Brain Bank, Centro Hospitalar Universitário de Santo António, Porto, Portugal
| |
Collapse
|
17
|
Muir RT, Callum JL, Yu AYX, Kapral MK, Swartz RH, Black SE, MacIntosh BJ, Fergusson DA, Kleinman S, Demchuk AD, Stys PK, Smith EE, Hill MD. Beta-Amyloid Related Neurodegenerative and Neurovascular Diseases: Potential Implications for Transfusion Medicine. Transfus Med Rev 2024; 38:150858. [PMID: 39413667 DOI: 10.1016/j.tmrv.2024.150858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2024] [Revised: 08/26/2024] [Accepted: 09/02/2024] [Indexed: 10/18/2024]
Abstract
Cerebral amyloid angiopathy (CAA) is a progressive cerebrovascular and neurodegenerative disorder that is caused by the aberrant accumulation of soluble beta-amyloid isoforms in the small vessel walls of the cerebral and cerebellar cortices and the leptomeninges. Vascular beta-amyloid deposition increases vulnerability to intracerebral hemorrhage (ICH). Clinically, CAA can be the underlying cause of up to half of spontaneous lobar ICHs and can also present with convexity subarachnoid hemorrhage, transient focal neurologic episodes and progressive cognitive decline leading to dementia. The majority of CAA is sporadic, with increasing prevalence with age and often coexists with Alzheimer's Disease (AD). Genetic and iatrogenic etiologies are rare. Cases of CAA and AD have been linked to the use of cadaveric pituitary hormone and later life iatrogenic CAA has also been described following early-life neurosurgical procedures with cadaveric dura grafts. Together these data suggest a capacity of beta-amyloid transmissibility. A recent study found that in over 1 million transfusion recipients from donors who later developed (i) >1 ICH or (ii) one ICH event and dementia, had an elevated risk of developing future ICH. Considering prior reports of transfusion associated variant-Creutzfeldt Jakob Disease in humans and in vivo evidence in sheep, coupled with emerging data supporting beta-amyloid's prion-like properties, raises the question of whether CAA could be transmissible by blood transfusion. This would also have implications for screening, especially in an era of emerging plasma biomarkers of cerebral amyloidosis. Given the public health concerns raised by this biologically plausible question, there is a need for future studies with well-characterized definitions - and temporal ascertainment - of CAA exposure and outcomes to examine whether CAA is transfusion-transmissible, and, if so, with what frequency and timing of onset.
Collapse
Affiliation(s)
- Ryan T Muir
- Calgary Stroke Program, Department of Clinical Neurosciences, Calgary, Alberta, Canada; Hotchkiss Brain Institute, Calgary, Alberta, Canada; Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
| | - Jeannie L Callum
- Department of Pathology and Molecular Medicine, Queen's University, Ontario, Canada; Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Research Program Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada
| | - Amy Y X Yu
- Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Research Program Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada; Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; ICES (formerly Institute for Clinical Evaluative Sciences), Toronto, Ontario, Canada
| | - Moira K Kapral
- ICES (formerly Institute for Clinical Evaluative Sciences), Toronto, Ontario, Canada; Department of Medicine, General Internal Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada
| | - Richard H Swartz
- Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Research Program Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada; Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; ICES (formerly Institute for Clinical Evaluative Sciences), Toronto, Ontario, Canada
| | - Sandra E Black
- Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Research Program Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada; Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
| | - Bradley J MacIntosh
- Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Research Program Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada
| | - Dean A Fergusson
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Steven Kleinman
- Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Andrew D Demchuk
- Calgary Stroke Program, Department of Clinical Neurosciences, Calgary, Alberta, Canada; Hotchkiss Brain Institute, Calgary, Alberta, Canada
| | - Peter K Stys
- Calgary Stroke Program, Department of Clinical Neurosciences, Calgary, Alberta, Canada; Hotchkiss Brain Institute, Calgary, Alberta, Canada
| | - Eric E Smith
- Calgary Stroke Program, Department of Clinical Neurosciences, Calgary, Alberta, Canada; Hotchkiss Brain Institute, Calgary, Alberta, Canada
| | - Michael D Hill
- Calgary Stroke Program, Department of Clinical Neurosciences, Calgary, Alberta, Canada; Hotchkiss Brain Institute, Calgary, Alberta, Canada; Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
| |
Collapse
|
18
|
Fandler-Höfler S, Ambler G, Banerjee G, Nash PS, Obergottsberger L, Wünsch G, Kiss C, Fabisch L, Kneihsl M, Zhang W, Ozkan H, Locatelli M, Du Y, Panteleienko L, Mendel R, Thiankhaw K, Simister RJ, Jäger HR, Enzinger C, Gattringer T, Werring DJ. Temporal and Spatial Clustering of Intracerebral Hemorrhage in Cerebral Amyloid Angiopathy. Neurology 2024; 103:e209770. [PMID: 39151104 PMCID: PMC11361829 DOI: 10.1212/wnl.0000000000209770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2024] [Accepted: 07/09/2024] [Indexed: 08/18/2024] Open
Abstract
OBJECTIVES Cerebral amyloid angiopathy (CAA)-associated lobar intracerebral hemorrhage (ICH) has a high risk of recurrence, but the underlying mechanisms remain uncertain. We, therefore, aimed to characterize patterns of recurrent ICH. METHODS We investigated early recurrent ICH (≥1 recurrent ICH event within 90 days of the index event) and ICH clusters (≥2 ICH events within 90 days at any time point) in 2 large cohorts of consecutive patients with first-ever ICH and available MRI. RESULTS In 682 included patients (median age 68 years, 40.3% female, median follow-up time 4.1 years), 18 (2.6%) had an early recurrent ICH, which was associated with higher age and CAA. In patients with probable CAA, the risk of early recurrent ICH was increased 5-fold within the first 3 months compared with during months 4-12 (hazard ratio 5.41, 95% CI 2.18-13.4) while no significant difference was observed in patients without CAA. In patients with an ICH cluster, we observed spatial clustering (recurrent ICH within close proximity of index ICH in 63.0%) and a tendency for multiple sequential hemorrhages (≥3 ICH foci within 3 months in 44.4%). DISCUSSION Our data provide evidence of both temporal and spatial clustering of ICH in CAA, suggesting a transient and localized active bleeding-prone process.
Collapse
Affiliation(s)
- Simon Fandler-Höfler
- From the Department of Neurology (S.F.-H., L.O., C.K., L.F., M.K., C.E., T.G.), Medical University of Graz, Austria; Stroke Research Centre (S.F.-H., G.B., P.S.N., W.Z., H.O., M.L., Y.D., L.P., R.M., K.T., R.J.S., D.J.W.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A.), University College London; MRC Prion Unit at UCL (G.B.), Institute of Prion Diseases, London, United Kingdom; Institute for Medical Informatics, Statistics and Documentation (G.W.), and Division of Neuroradiology, Vascular and Interventional Radiology (M.K.), Department of Radiology, Medical University of Graz, Austria; and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Gareth Ambler
- From the Department of Neurology (S.F.-H., L.O., C.K., L.F., M.K., C.E., T.G.), Medical University of Graz, Austria; Stroke Research Centre (S.F.-H., G.B., P.S.N., W.Z., H.O., M.L., Y.D., L.P., R.M., K.T., R.J.S., D.J.W.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A.), University College London; MRC Prion Unit at UCL (G.B.), Institute of Prion Diseases, London, United Kingdom; Institute for Medical Informatics, Statistics and Documentation (G.W.), and Division of Neuroradiology, Vascular and Interventional Radiology (M.K.), Department of Radiology, Medical University of Graz, Austria; and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Gargi Banerjee
- From the Department of Neurology (S.F.-H., L.O., C.K., L.F., M.K., C.E., T.G.), Medical University of Graz, Austria; Stroke Research Centre (S.F.-H., G.B., P.S.N., W.Z., H.O., M.L., Y.D., L.P., R.M., K.T., R.J.S., D.J.W.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A.), University College London; MRC Prion Unit at UCL (G.B.), Institute of Prion Diseases, London, United Kingdom; Institute for Medical Informatics, Statistics and Documentation (G.W.), and Division of Neuroradiology, Vascular and Interventional Radiology (M.K.), Department of Radiology, Medical University of Graz, Austria; and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Philip S Nash
- From the Department of Neurology (S.F.-H., L.O., C.K., L.F., M.K., C.E., T.G.), Medical University of Graz, Austria; Stroke Research Centre (S.F.-H., G.B., P.S.N., W.Z., H.O., M.L., Y.D., L.P., R.M., K.T., R.J.S., D.J.W.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A.), University College London; MRC Prion Unit at UCL (G.B.), Institute of Prion Diseases, London, United Kingdom; Institute for Medical Informatics, Statistics and Documentation (G.W.), and Division of Neuroradiology, Vascular and Interventional Radiology (M.K.), Department of Radiology, Medical University of Graz, Austria; and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Lena Obergottsberger
- From the Department of Neurology (S.F.-H., L.O., C.K., L.F., M.K., C.E., T.G.), Medical University of Graz, Austria; Stroke Research Centre (S.F.-H., G.B., P.S.N., W.Z., H.O., M.L., Y.D., L.P., R.M., K.T., R.J.S., D.J.W.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A.), University College London; MRC Prion Unit at UCL (G.B.), Institute of Prion Diseases, London, United Kingdom; Institute for Medical Informatics, Statistics and Documentation (G.W.), and Division of Neuroradiology, Vascular and Interventional Radiology (M.K.), Department of Radiology, Medical University of Graz, Austria; and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Gerit Wünsch
- From the Department of Neurology (S.F.-H., L.O., C.K., L.F., M.K., C.E., T.G.), Medical University of Graz, Austria; Stroke Research Centre (S.F.-H., G.B., P.S.N., W.Z., H.O., M.L., Y.D., L.P., R.M., K.T., R.J.S., D.J.W.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A.), University College London; MRC Prion Unit at UCL (G.B.), Institute of Prion Diseases, London, United Kingdom; Institute for Medical Informatics, Statistics and Documentation (G.W.), and Division of Neuroradiology, Vascular and Interventional Radiology (M.K.), Department of Radiology, Medical University of Graz, Austria; and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Christian Kiss
- From the Department of Neurology (S.F.-H., L.O., C.K., L.F., M.K., C.E., T.G.), Medical University of Graz, Austria; Stroke Research Centre (S.F.-H., G.B., P.S.N., W.Z., H.O., M.L., Y.D., L.P., R.M., K.T., R.J.S., D.J.W.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A.), University College London; MRC Prion Unit at UCL (G.B.), Institute of Prion Diseases, London, United Kingdom; Institute for Medical Informatics, Statistics and Documentation (G.W.), and Division of Neuroradiology, Vascular and Interventional Radiology (M.K.), Department of Radiology, Medical University of Graz, Austria; and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Linda Fabisch
- From the Department of Neurology (S.F.-H., L.O., C.K., L.F., M.K., C.E., T.G.), Medical University of Graz, Austria; Stroke Research Centre (S.F.-H., G.B., P.S.N., W.Z., H.O., M.L., Y.D., L.P., R.M., K.T., R.J.S., D.J.W.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A.), University College London; MRC Prion Unit at UCL (G.B.), Institute of Prion Diseases, London, United Kingdom; Institute for Medical Informatics, Statistics and Documentation (G.W.), and Division of Neuroradiology, Vascular and Interventional Radiology (M.K.), Department of Radiology, Medical University of Graz, Austria; and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Markus Kneihsl
- From the Department of Neurology (S.F.-H., L.O., C.K., L.F., M.K., C.E., T.G.), Medical University of Graz, Austria; Stroke Research Centre (S.F.-H., G.B., P.S.N., W.Z., H.O., M.L., Y.D., L.P., R.M., K.T., R.J.S., D.J.W.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A.), University College London; MRC Prion Unit at UCL (G.B.), Institute of Prion Diseases, London, United Kingdom; Institute for Medical Informatics, Statistics and Documentation (G.W.), and Division of Neuroradiology, Vascular and Interventional Radiology (M.K.), Department of Radiology, Medical University of Graz, Austria; and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Wenpeng Zhang
- From the Department of Neurology (S.F.-H., L.O., C.K., L.F., M.K., C.E., T.G.), Medical University of Graz, Austria; Stroke Research Centre (S.F.-H., G.B., P.S.N., W.Z., H.O., M.L., Y.D., L.P., R.M., K.T., R.J.S., D.J.W.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A.), University College London; MRC Prion Unit at UCL (G.B.), Institute of Prion Diseases, London, United Kingdom; Institute for Medical Informatics, Statistics and Documentation (G.W.), and Division of Neuroradiology, Vascular and Interventional Radiology (M.K.), Department of Radiology, Medical University of Graz, Austria; and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Hatice Ozkan
- From the Department of Neurology (S.F.-H., L.O., C.K., L.F., M.K., C.E., T.G.), Medical University of Graz, Austria; Stroke Research Centre (S.F.-H., G.B., P.S.N., W.Z., H.O., M.L., Y.D., L.P., R.M., K.T., R.J.S., D.J.W.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A.), University College London; MRC Prion Unit at UCL (G.B.), Institute of Prion Diseases, London, United Kingdom; Institute for Medical Informatics, Statistics and Documentation (G.W.), and Division of Neuroradiology, Vascular and Interventional Radiology (M.K.), Department of Radiology, Medical University of Graz, Austria; and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Martina Locatelli
- From the Department of Neurology (S.F.-H., L.O., C.K., L.F., M.K., C.E., T.G.), Medical University of Graz, Austria; Stroke Research Centre (S.F.-H., G.B., P.S.N., W.Z., H.O., M.L., Y.D., L.P., R.M., K.T., R.J.S., D.J.W.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A.), University College London; MRC Prion Unit at UCL (G.B.), Institute of Prion Diseases, London, United Kingdom; Institute for Medical Informatics, Statistics and Documentation (G.W.), and Division of Neuroradiology, Vascular and Interventional Radiology (M.K.), Department of Radiology, Medical University of Graz, Austria; and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Yang Du
- From the Department of Neurology (S.F.-H., L.O., C.K., L.F., M.K., C.E., T.G.), Medical University of Graz, Austria; Stroke Research Centre (S.F.-H., G.B., P.S.N., W.Z., H.O., M.L., Y.D., L.P., R.M., K.T., R.J.S., D.J.W.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A.), University College London; MRC Prion Unit at UCL (G.B.), Institute of Prion Diseases, London, United Kingdom; Institute for Medical Informatics, Statistics and Documentation (G.W.), and Division of Neuroradiology, Vascular and Interventional Radiology (M.K.), Department of Radiology, Medical University of Graz, Austria; and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Larysa Panteleienko
- From the Department of Neurology (S.F.-H., L.O., C.K., L.F., M.K., C.E., T.G.), Medical University of Graz, Austria; Stroke Research Centre (S.F.-H., G.B., P.S.N., W.Z., H.O., M.L., Y.D., L.P., R.M., K.T., R.J.S., D.J.W.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A.), University College London; MRC Prion Unit at UCL (G.B.), Institute of Prion Diseases, London, United Kingdom; Institute for Medical Informatics, Statistics and Documentation (G.W.), and Division of Neuroradiology, Vascular and Interventional Radiology (M.K.), Department of Radiology, Medical University of Graz, Austria; and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Rom Mendel
- From the Department of Neurology (S.F.-H., L.O., C.K., L.F., M.K., C.E., T.G.), Medical University of Graz, Austria; Stroke Research Centre (S.F.-H., G.B., P.S.N., W.Z., H.O., M.L., Y.D., L.P., R.M., K.T., R.J.S., D.J.W.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A.), University College London; MRC Prion Unit at UCL (G.B.), Institute of Prion Diseases, London, United Kingdom; Institute for Medical Informatics, Statistics and Documentation (G.W.), and Division of Neuroradiology, Vascular and Interventional Radiology (M.K.), Department of Radiology, Medical University of Graz, Austria; and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Kitti Thiankhaw
- From the Department of Neurology (S.F.-H., L.O., C.K., L.F., M.K., C.E., T.G.), Medical University of Graz, Austria; Stroke Research Centre (S.F.-H., G.B., P.S.N., W.Z., H.O., M.L., Y.D., L.P., R.M., K.T., R.J.S., D.J.W.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A.), University College London; MRC Prion Unit at UCL (G.B.), Institute of Prion Diseases, London, United Kingdom; Institute for Medical Informatics, Statistics and Documentation (G.W.), and Division of Neuroradiology, Vascular and Interventional Radiology (M.K.), Department of Radiology, Medical University of Graz, Austria; and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Robert J Simister
- From the Department of Neurology (S.F.-H., L.O., C.K., L.F., M.K., C.E., T.G.), Medical University of Graz, Austria; Stroke Research Centre (S.F.-H., G.B., P.S.N., W.Z., H.O., M.L., Y.D., L.P., R.M., K.T., R.J.S., D.J.W.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A.), University College London; MRC Prion Unit at UCL (G.B.), Institute of Prion Diseases, London, United Kingdom; Institute for Medical Informatics, Statistics and Documentation (G.W.), and Division of Neuroradiology, Vascular and Interventional Radiology (M.K.), Department of Radiology, Medical University of Graz, Austria; and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Hans Rolf Jäger
- From the Department of Neurology (S.F.-H., L.O., C.K., L.F., M.K., C.E., T.G.), Medical University of Graz, Austria; Stroke Research Centre (S.F.-H., G.B., P.S.N., W.Z., H.O., M.L., Y.D., L.P., R.M., K.T., R.J.S., D.J.W.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A.), University College London; MRC Prion Unit at UCL (G.B.), Institute of Prion Diseases, London, United Kingdom; Institute for Medical Informatics, Statistics and Documentation (G.W.), and Division of Neuroradiology, Vascular and Interventional Radiology (M.K.), Department of Radiology, Medical University of Graz, Austria; and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Christian Enzinger
- From the Department of Neurology (S.F.-H., L.O., C.K., L.F., M.K., C.E., T.G.), Medical University of Graz, Austria; Stroke Research Centre (S.F.-H., G.B., P.S.N., W.Z., H.O., M.L., Y.D., L.P., R.M., K.T., R.J.S., D.J.W.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A.), University College London; MRC Prion Unit at UCL (G.B.), Institute of Prion Diseases, London, United Kingdom; Institute for Medical Informatics, Statistics and Documentation (G.W.), and Division of Neuroradiology, Vascular and Interventional Radiology (M.K.), Department of Radiology, Medical University of Graz, Austria; and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Thomas Gattringer
- From the Department of Neurology (S.F.-H., L.O., C.K., L.F., M.K., C.E., T.G.), Medical University of Graz, Austria; Stroke Research Centre (S.F.-H., G.B., P.S.N., W.Z., H.O., M.L., Y.D., L.P., R.M., K.T., R.J.S., D.J.W.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A.), University College London; MRC Prion Unit at UCL (G.B.), Institute of Prion Diseases, London, United Kingdom; Institute for Medical Informatics, Statistics and Documentation (G.W.), and Division of Neuroradiology, Vascular and Interventional Radiology (M.K.), Department of Radiology, Medical University of Graz, Austria; and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - David J Werring
- From the Department of Neurology (S.F.-H., L.O., C.K., L.F., M.K., C.E., T.G.), Medical University of Graz, Austria; Stroke Research Centre (S.F.-H., G.B., P.S.N., W.Z., H.O., M.L., Y.D., L.P., R.M., K.T., R.J.S., D.J.W.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology; Department of Statistical Science (G.A.), University College London; MRC Prion Unit at UCL (G.B.), Institute of Prion Diseases, London, United Kingdom; Institute for Medical Informatics, Statistics and Documentation (G.W.), and Division of Neuroradiology, Vascular and Interventional Radiology (M.K.), Department of Radiology, Medical University of Graz, Austria; and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom
| |
Collapse
|
19
|
Wang ZJ, Hu X, Xie YF, Yao WJ, Deng L, Li ZQ, Pu MJ, Lv XN, Hu ZC, Zhang JT, Li Q. Prevalence of small vessel disease and incidental DWI-positive lesions in patients with aneurysmal subarachnoid hemorrhage versus intracerebral hemorrhage. Eur Stroke J 2024; 9:639-647. [PMID: 38372251 PMCID: PMC11418497 DOI: 10.1177/23969873241232327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Accepted: 01/25/2024] [Indexed: 02/20/2024] Open
Abstract
INTRODUCTION Aneurysmal subarachnoid hemorrhage (aSAH) and intracerebral hemorrhage (ICH) are main forms of hemorrhagic stroke. Data regarding cerebral small vessel disease (SVD) burden and incidental small lesions on diffusion-weighted imaging (DWI) following aSAH are sparse. PATIENTS AND METHODS We retrospectively analyzed a prospective cohort of aSAH and ICH patients with brain MRI within 30 days after onset from March 2015 to January 2023. White matter hyperintensity (WMH), lacune, perivascular space, cerebral microbleed (CMB), total SVD score, and incidental DWI lesions were assessed and compared between aSAH and ICH. Clinical and radiological characteristics associated with small DWI lesions in aSAH were investigated. RESULTS We included 180 patients with aSAH (median age [IQR] 53 [47-61] years) and 299 with ICH (63 [53-73] years). DWI lesions were more common in aSAH than ICH (47.8% vs 14.4%, p < 0.001). Higher total SVD score was associated with ICH versus aSAH irrespective of hematoma location, whereas DWI lesions and strictly lobar CMBs were correlated with aSAH. Multivariable analysis showed that shorter time from onset to MRI, anterior circulation aneurysm rupture, CMB ⩾ 5, and total SVD score were associated with DWI lesions in aSAH. DISCUSSION AND CONCLUSION Incidental DWI lesions and strictly lobar CMBs were more frequent in aSAH versus ICH whereas ICH had higher SVD burden. Incidental DWI lesions in aSAH were associated with multiple clinical and imaging factors. Longitudinal studies to investigate the dynamic change and prognostic value of the covert hemorrhagic and ischemic lesions in aSAH seem justified.
Collapse
Affiliation(s)
- Zi-Jie Wang
- Department of Neurology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
- Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Xiao Hu
- Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Yan-Fang Xie
- Department of Neurology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
| | - Wen-Jun Yao
- Department of Radiology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
| | - Lan Deng
- Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Zuo-Qiao Li
- Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Ming-Jun Pu
- Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Xin-Ni Lv
- Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Zi-Cheng Hu
- Department of Neurology, People’s Hospital of Hechuan, Chongqing, China
| | - Jiang-Tao Zhang
- Department of Neurology, Chengde Central Hospital, Chengde, Hebei, China
| | - Qi Li
- Department of Neurology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
- Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
- Chongqing Key Laboratory of Cerebrovascular Disease Research, Chongqing, China
| |
Collapse
|
20
|
Li Y, Cho SM, Avadhani R, Ali H, Hao Y, Murthy SB, Goldstein JN, Xia F, Hu X, Ullman NL, Awad I, Hanley D, Ziai WC. Cerebral small vessel disease modifies outcomes after minimally invasive surgery for intracerebral haemorrhage. Stroke Vasc Neurol 2024; 9:446-456. [PMID: 37949482 PMCID: PMC11420921 DOI: 10.1136/svn-2023-002463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Accepted: 08/29/2023] [Indexed: 11/12/2023] Open
Abstract
BACKGROUND Minimally invasive surgery (MIS) for spontaneous supratentorial intracerebral haemorrhage (ICH) is controversial but may be beneficial if end-of-treatment (EOT) haematoma volume is reduced to ≤15 mL. We explored whether MRI findings of cerebral small vessel disease (CSVD) modify the effect of MIS on long-term outcomes. METHODS Prespecified blinded subgroup analysis of 288 subjects with qualified imaging sequences from the phase 3 Minimally Invasive Surgery Plus Alteplase for Intracerebral Haemorrhage Evacuation (MISTIE) trial. We tested for heterogeneity in the effects of MIS and MIS+EOT volume ≤15 mL on the trial's primary outcome of good versus poor function at 1 year by the presence of single CSVD features and CSVD scores using multivariable models. RESULTS Of 499 patients enrolled in MISTIE III, 288 patients had MRI, 149 (51.7%) randomised to MIS and 139 (48.3%) to standard medical care (SMC). Median (IQR) ICH volume was 42 (30-53) mL. In the full MRI cohort, there was no statistically significant heterogeneity in the effects of MIS versus SMC on 1-year outcomes by any specific CSVD feature or by CSVD scores (all Pinteraction >0.05). In 94 MIS patients with EOT ICH volume ≤15 mL, significant reduction in odds of poor outcome was found with cerebral amyloid angiopathy score <2 (OR, 0.14 (0.05-0.42); Pinteraction=0.006), absence of lacunes (OR, 0.37 (0.18-0.80); Pinteraction=0.02) and absence of severe white matter hyperintensities (WMHs) (OR, 0.22 (0.08-0.58); Pinteraction=0.03). CONCLUSIONS Following successful haematoma reduction by MIS, we found significantly lower odds of poor functional outcome with lower total burden of CSVD in addition to absence of lacunes and severe WMHs. CSVD features may have utility for prognostication and patient selection in clinical trials of MIS.
Collapse
Affiliation(s)
- Yunke Li
- The George Institute for Global Health, Beijing, China
| | - Sung-Min Cho
- Department of Neurology, Division of Neurocritical Care, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
| | - Radhika Avadhani
- Department of Neurology, Division of Brain Injury Outcomes, Johns Hopkins Medical Institutions Campus, Baltimore, Maryland, USA
| | - Hassan Ali
- Department of Neurology, Division of Brain Injury Outcomes, Johns Hopkins Medical Institutions Campus, Baltimore, Maryland, USA
| | - Yi Hao
- Department of Neurology, Division of Brain Injury Outcomes, Johns Hopkins Medical Institutions Campus, Baltimore, Maryland, USA
| | - Santosh B Murthy
- Department of Neurology, Weill Cornell Medical College, New York, New York, USA
| | - Joshua N Goldstein
- Department of Emergency Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Fan Xia
- Department of Neurosurgery, West China Hospital of Medicine, Chengdu, Sichuan, China
| | - Xin Hu
- Department of Neurosurgery, West China Hospital of Medicine, Chengdu, Sichuan, China
| | - Natalie L Ullman
- Department of Neurology, Division of Brain Injury Outcomes, Johns Hopkins Medical Institutions Campus, Baltimore, Maryland, USA
| | - Issam Awad
- Department of Neurosurgery, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
| | - Daniel Hanley
- Department of Neurology, Division of Brain Injury Outcomes, Johns Hopkins Medical Institutions Campus, Baltimore, Maryland, USA
| | - Wendy C Ziai
- Department of Neurology, Division of Neurocritical Care, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
- Department of Neurology, Division of Brain Injury Outcomes, Johns Hopkins Medical Institutions Campus, Baltimore, Maryland, USA
| |
Collapse
|
21
|
Jin Y, Huang YH, Chen YP, Zhang YD, Li J, Yang KC, Ye X, Jin LH, Wu J, Yuan CZ, Gao F, Tong LS. Combined effect of cortical superficial siderosis and cerebral microbleed on short-term and long-term outcomes after intracerebral haemorrhage. Stroke Vasc Neurol 2024; 9:429-438. [PMID: 37949481 PMCID: PMC11423268 DOI: 10.1136/svn-2023-002439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2023] [Accepted: 10/24/2023] [Indexed: 11/12/2023] Open
Abstract
BACKGROUND AND PURPOSE Cortical superficial siderosis (cSS) and cerebral microbleed (CMB) have distinct effects on intracerebral haemorrhage (ICH). We aim to investigate the combined effect of cSS and CMB on outcomes after ICH. METHODS Based on a single-centre stroke registry database, patients with spontaneous ICH who had CT scan within 48 hours after ictus and MRI subsequently were identified. Eligible patients were divided into four groups (cSS-CMB-, cSS-CMB+, cSS+CMB-, cSS+CMB+) according to cSS and CMB on susceptibility-weighted image of MRI. Primary outcomes were haematoma volume on admission and unfavourable outcome defined as modified Rankin Scale scores ≥3 at 3 months. Secondary outcomes were all-cause death, recurrence of stroke and ICH during follow-up (median follow-up 2.0 years, IQR 1.0-3.0 years). RESULTS A total of 673 patients were identified from 1044 patients with spontaneous ICH. 131 (19.5%) had cSS and 468 (69.5%) had CMB. Patients with cSS+CMB+ had the highest rate of poor outcome at 3 months, as well as all-cause death, recurrent stroke and ICH during follow-up. In cSS- patients, CMB was associated with smaller haematoma (β -0.13; 95% CI -0.22 to -0.03; p=0.009), but it still increased risks of recurrent ICH (OR 4.6; 95% CI 1.3 to 15.6; p=0.015) and stroke (OR 2.0; 95% CI 1.0 to 4.0; p=0.049). These effects of CMB became unremarkable in the context of cSS+. CONCLUSIONS Patients with different combinations of cSS and CMB have distinct patterns of short-term and long-term outcomes. Although CMB is related to restrained haematoma, it does not improve long-term outcomes. TRIAL REGISTRATION NUMBER NCT04803292.
Collapse
Affiliation(s)
- Yujia Jin
- Neurology Department, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China
| | - Yu-Hui Huang
- School of Public Health, Zhejiang University, Hangzhou, China
| | - Yu-Ping Chen
- Neurology Department, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China
| | - Yao-Dan Zhang
- School of Public Health, Zhejiang University, Hangzhou, China
| | - Jiawen Li
- Neurology Department, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China
| | - Kai-Cheng Yang
- Neurology Department, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China
| | - Xianghua Ye
- Neurology Department, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China
| | - Lu-Hang Jin
- Neurology Department, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China
| | - Jian Wu
- Department of Neurology, Tiantai People's Hospital of Zhejiang Province, Taizhou, China
| | | | - Feng Gao
- Neurology Department, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China
| | - Lu-Sha Tong
- Neurology Department, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China
| |
Collapse
|
22
|
Naftali J, Barnea R, Leader A, Eliahou R, Pardo K, Tolkovsky A, Hasminski V, Raphaeli G, Bloch S, Shochat T, Saliba W, Auriel E. Association of Acute Incidental Cerebral Microinfarcts With Subsequent Ischemic Stroke in Patients With Cancer: A Population-Based Study. Neurology 2024; 103:e209655. [PMID: 38981073 DOI: 10.1212/wnl.0000000000209655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/11/2024] Open
Abstract
BACKGROUND AND OBJECTIVES Incidental diffuse-weighted imaging (DWI)-positive subcortical and cortical lesions, or acute incidental cerebral microinfarcts (CMIs), are a common type of brain ischemia, which can be detected on magnetic resonance DWI for approximately 2 weeks after occurrence. Acute incidental CMI was found to be more common in patients with cancer. Whether acute incidental CMI predicts future ischemic stroke is still unknown. We aimed to examine the association between acute incidental CMI in patients with cancer and subsequent ischemic stroke or transient ischemic attack (TIA). METHODS This is a retrospective cohort study. We used Clalit Health Services records, representing over half of the Israeli population, to identify adults with lung, breast, pancreatic, or colon cancer who underwent brain MRI between January 2014 and April 2020. We included patients who underwent scan between 1 year before cancer diagnosis and 1 year after diagnosis. Primary outcome was ischemic stroke or TIA using International Classification of Diseases, Ninth Revision codes. Secondary outcomes were intracranial hemorrhage (ICH) and mortality. Records were followed from first MRI until primary outcome, death, or end of follow-up (January 2023). Cox proportional hazards models were used to calculate hazard ratio (HR) for patients with and without acute incidental CMI, as a time-dependent covariate. RESULTS The study cohort included 1,618 patients with cancer, among whom, 59 (3.6%) had acute incidental CMI on at least 1 brain MRI. The median (interquartile range) time from acute incidental CMI to stroke or TIA was 26 days (14-84). On multivariable analysis, patients with acute incidental CMI had a higher stroke or TIA risk (HR 2.97, 95% CI 1.08-8.18, p = 0.035) compared with their non-CMI counterparts. Acute incidental CMIs were also associated with mortality after multivariable analysis (HR 2.76, 95% CI 2.06-3.71, p < 0.001); no association with ICH was found. DISCUSSION Acute incidental CMI on brain MRI in patients with active cancer is associated with an increased risk of near-future ischemic stroke or TIA and mortality. This finding might suggest that randomly detected acute incidental CMI in patients with cancer may guide primary cerebrovascular risk prevention and etiologic workup.
Collapse
Affiliation(s)
- Jonathan Naftali
- From the Departments of Neurology (J.N., R.B., K.P., A.T., G.R., E.A.) and Radiology (R.E., V.H.), Rabin Medical Center (T.S.), Petach Tikva; Faculty of Medicine (J.N., R.B., R.E., V.H., G.R., E.A.), Tel Aviv University, Israel; Department of Medicine (A.L.), Hematology Service, Memorial Sloan Kettering Cancer Center, New York City, NY; Departments of Neurology (S.B.) and Community Medicine and Epidemiology (W.S.), Lady Davis Carmel Medical Center, Haifa; and Ruth and Bruce Rappaport Faculty of Medicine (S.B., W.S.), Technion-Israel Institute of Technology, Haifa, Israel
| | - Rani Barnea
- From the Departments of Neurology (J.N., R.B., K.P., A.T., G.R., E.A.) and Radiology (R.E., V.H.), Rabin Medical Center (T.S.), Petach Tikva; Faculty of Medicine (J.N., R.B., R.E., V.H., G.R., E.A.), Tel Aviv University, Israel; Department of Medicine (A.L.), Hematology Service, Memorial Sloan Kettering Cancer Center, New York City, NY; Departments of Neurology (S.B.) and Community Medicine and Epidemiology (W.S.), Lady Davis Carmel Medical Center, Haifa; and Ruth and Bruce Rappaport Faculty of Medicine (S.B., W.S.), Technion-Israel Institute of Technology, Haifa, Israel
| | - Avi Leader
- From the Departments of Neurology (J.N., R.B., K.P., A.T., G.R., E.A.) and Radiology (R.E., V.H.), Rabin Medical Center (T.S.), Petach Tikva; Faculty of Medicine (J.N., R.B., R.E., V.H., G.R., E.A.), Tel Aviv University, Israel; Department of Medicine (A.L.), Hematology Service, Memorial Sloan Kettering Cancer Center, New York City, NY; Departments of Neurology (S.B.) and Community Medicine and Epidemiology (W.S.), Lady Davis Carmel Medical Center, Haifa; and Ruth and Bruce Rappaport Faculty of Medicine (S.B., W.S.), Technion-Israel Institute of Technology, Haifa, Israel
| | - Ruth Eliahou
- From the Departments of Neurology (J.N., R.B., K.P., A.T., G.R., E.A.) and Radiology (R.E., V.H.), Rabin Medical Center (T.S.), Petach Tikva; Faculty of Medicine (J.N., R.B., R.E., V.H., G.R., E.A.), Tel Aviv University, Israel; Department of Medicine (A.L.), Hematology Service, Memorial Sloan Kettering Cancer Center, New York City, NY; Departments of Neurology (S.B.) and Community Medicine and Epidemiology (W.S.), Lady Davis Carmel Medical Center, Haifa; and Ruth and Bruce Rappaport Faculty of Medicine (S.B., W.S.), Technion-Israel Institute of Technology, Haifa, Israel
| | - Keshet Pardo
- From the Departments of Neurology (J.N., R.B., K.P., A.T., G.R., E.A.) and Radiology (R.E., V.H.), Rabin Medical Center (T.S.), Petach Tikva; Faculty of Medicine (J.N., R.B., R.E., V.H., G.R., E.A.), Tel Aviv University, Israel; Department of Medicine (A.L.), Hematology Service, Memorial Sloan Kettering Cancer Center, New York City, NY; Departments of Neurology (S.B.) and Community Medicine and Epidemiology (W.S.), Lady Davis Carmel Medical Center, Haifa; and Ruth and Bruce Rappaport Faculty of Medicine (S.B., W.S.), Technion-Israel Institute of Technology, Haifa, Israel
| | - Assaf Tolkovsky
- From the Departments of Neurology (J.N., R.B., K.P., A.T., G.R., E.A.) and Radiology (R.E., V.H.), Rabin Medical Center (T.S.), Petach Tikva; Faculty of Medicine (J.N., R.B., R.E., V.H., G.R., E.A.), Tel Aviv University, Israel; Department of Medicine (A.L.), Hematology Service, Memorial Sloan Kettering Cancer Center, New York City, NY; Departments of Neurology (S.B.) and Community Medicine and Epidemiology (W.S.), Lady Davis Carmel Medical Center, Haifa; and Ruth and Bruce Rappaport Faculty of Medicine (S.B., W.S.), Technion-Israel Institute of Technology, Haifa, Israel
| | - Vadim Hasminski
- From the Departments of Neurology (J.N., R.B., K.P., A.T., G.R., E.A.) and Radiology (R.E., V.H.), Rabin Medical Center (T.S.), Petach Tikva; Faculty of Medicine (J.N., R.B., R.E., V.H., G.R., E.A.), Tel Aviv University, Israel; Department of Medicine (A.L.), Hematology Service, Memorial Sloan Kettering Cancer Center, New York City, NY; Departments of Neurology (S.B.) and Community Medicine and Epidemiology (W.S.), Lady Davis Carmel Medical Center, Haifa; and Ruth and Bruce Rappaport Faculty of Medicine (S.B., W.S.), Technion-Israel Institute of Technology, Haifa, Israel
| | - Guy Raphaeli
- From the Departments of Neurology (J.N., R.B., K.P., A.T., G.R., E.A.) and Radiology (R.E., V.H.), Rabin Medical Center (T.S.), Petach Tikva; Faculty of Medicine (J.N., R.B., R.E., V.H., G.R., E.A.), Tel Aviv University, Israel; Department of Medicine (A.L.), Hematology Service, Memorial Sloan Kettering Cancer Center, New York City, NY; Departments of Neurology (S.B.) and Community Medicine and Epidemiology (W.S.), Lady Davis Carmel Medical Center, Haifa; and Ruth and Bruce Rappaport Faculty of Medicine (S.B., W.S.), Technion-Israel Institute of Technology, Haifa, Israel
| | - Sivan Bloch
- From the Departments of Neurology (J.N., R.B., K.P., A.T., G.R., E.A.) and Radiology (R.E., V.H.), Rabin Medical Center (T.S.), Petach Tikva; Faculty of Medicine (J.N., R.B., R.E., V.H., G.R., E.A.), Tel Aviv University, Israel; Department of Medicine (A.L.), Hematology Service, Memorial Sloan Kettering Cancer Center, New York City, NY; Departments of Neurology (S.B.) and Community Medicine and Epidemiology (W.S.), Lady Davis Carmel Medical Center, Haifa; and Ruth and Bruce Rappaport Faculty of Medicine (S.B., W.S.), Technion-Israel Institute of Technology, Haifa, Israel
| | - Tzippy Shochat
- From the Departments of Neurology (J.N., R.B., K.P., A.T., G.R., E.A.) and Radiology (R.E., V.H.), Rabin Medical Center (T.S.), Petach Tikva; Faculty of Medicine (J.N., R.B., R.E., V.H., G.R., E.A.), Tel Aviv University, Israel; Department of Medicine (A.L.), Hematology Service, Memorial Sloan Kettering Cancer Center, New York City, NY; Departments of Neurology (S.B.) and Community Medicine and Epidemiology (W.S.), Lady Davis Carmel Medical Center, Haifa; and Ruth and Bruce Rappaport Faculty of Medicine (S.B., W.S.), Technion-Israel Institute of Technology, Haifa, Israel
| | - Walid Saliba
- From the Departments of Neurology (J.N., R.B., K.P., A.T., G.R., E.A.) and Radiology (R.E., V.H.), Rabin Medical Center (T.S.), Petach Tikva; Faculty of Medicine (J.N., R.B., R.E., V.H., G.R., E.A.), Tel Aviv University, Israel; Department of Medicine (A.L.), Hematology Service, Memorial Sloan Kettering Cancer Center, New York City, NY; Departments of Neurology (S.B.) and Community Medicine and Epidemiology (W.S.), Lady Davis Carmel Medical Center, Haifa; and Ruth and Bruce Rappaport Faculty of Medicine (S.B., W.S.), Technion-Israel Institute of Technology, Haifa, Israel
| | - Eitan Auriel
- From the Departments of Neurology (J.N., R.B., K.P., A.T., G.R., E.A.) and Radiology (R.E., V.H.), Rabin Medical Center (T.S.), Petach Tikva; Faculty of Medicine (J.N., R.B., R.E., V.H., G.R., E.A.), Tel Aviv University, Israel; Department of Medicine (A.L.), Hematology Service, Memorial Sloan Kettering Cancer Center, New York City, NY; Departments of Neurology (S.B.) and Community Medicine and Epidemiology (W.S.), Lady Davis Carmel Medical Center, Haifa; and Ruth and Bruce Rappaport Faculty of Medicine (S.B., W.S.), Technion-Israel Institute of Technology, Haifa, Israel
| |
Collapse
|
23
|
Lee DH, Lee EC, Park SW, Lee JY, Lee MR, Oh JS. Pathogenesis of Cerebral Small Vessel Disease: Role of the Glymphatic System Dysfunction. Int J Mol Sci 2024; 25:8752. [PMID: 39201439 PMCID: PMC11354389 DOI: 10.3390/ijms25168752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2024] [Revised: 08/02/2024] [Accepted: 08/08/2024] [Indexed: 09/02/2024] Open
Abstract
Cerebral small vessel disease (CSVD) is a group of pathologies that affect the cerebral blood vessels. CSVD accounts for 25% of strokes and contributes to 45% of dementia. However, the pathogenesis of CSVD remains unclear, involving a variety of complex mechanisms. CSVD may result from dysfunction in the glymphatic system (GS). The GS contains aquaporin-4 (AQP-4), which is in the perivascular space, at the endfeet of the astrocyte. The GS contributes to the removal of waste products from the central nervous system, occupying perivascular spaces and regulating the exchange and movement of cerebrospinal fluid and interstitial fluid. The GS involves astrocytes and aquaporin channels, which are components of the blood-brain barrier, and problems with them may constitute the pathogenesis of CSVD. Vascular risk factors, including diabetes, dilate the perivascular space, disrupting the glymphatic system and the active regulation of AQP-4. CSVD exacerbation due to disorders of the GS is associated with multiple vasculopathies. Dysfunction of the glymphatic system and AQP-4 interferes with the functioning of the blood-brain barrier, which exacerbates CSVD. In a long-term follow-up of CSVD patients with microbleeds, lacunar infarcts, and white matter hyperintensity, several vascular risk factors, including hypertension, increased the risk of ischemic stroke. Dysfunction of the GS may be the cause of CSVD; however, the underlying treatment needs to be studied further.
Collapse
Affiliation(s)
- Dong-Hun Lee
- Industry-Academic Cooperation Foundation, The Catholic University of Korea, 222, Banpo-daro, Seocho-gu, Seoul 06591, Republic of Korea
| | - Eun Chae Lee
- Department of Medical Life Sciences, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
| | - Sang-Won Park
- Department of Neurosurgery, Uijeongbu St. Mary’s Hospital, College of Medicine, 271 Cheonbo-ro, Uijeongbu 11765, Republic of Korea
| | - Ji Young Lee
- Department of Neurosurgery, Uijeongbu St. Mary’s Hospital, College of Medicine, 271 Cheonbo-ro, Uijeongbu 11765, Republic of Korea
| | - Man Ryul Lee
- Soonchunhyang Institute of Medi-bio Science (SIMS), Soon Chun Hyang University, Cheonan 31151, Republic of Korea
| | - Jae Sang Oh
- Department of Neurosurgery, Uijeongbu St. Mary’s Hospital, College of Medicine, 271 Cheonbo-ro, Uijeongbu 11765, Republic of Korea
| |
Collapse
|
24
|
Wu J, Liu Z, Yao M, Zhu Y, Peng B, Ni J. Clinical characteristics of cerebral amyloid angiopathy and risk factors of cerebral amyloid angiopathy related intracerebral hemorrhage. J Neurol 2024; 271:5025-5034. [PMID: 38796800 DOI: 10.1007/s00415-024-12451-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2024] [Revised: 05/14/2024] [Accepted: 05/16/2024] [Indexed: 05/29/2024]
Abstract
OBJECTIVES There is limited understanding of the differences between cerebral amyloid angiopathy (CAA) with and without intracerebral hemorrhage (ICH). This article aimed to describe the characteristics of CAA and identify the risk factors of CAA-ICH in a multicenter cohort. METHODS Patients consecutively enrolled in the national multicenter prospective Cerebral Small Vessel Disease Cohort Study who met the Boston diagnostic criteria for CAA or CAA-related inflammation were included in this study. The demographic characteristics and clinical data were collected. The clinical and radiographic differences between CAA with and without ICH were compared to identify the risk factors for CAA-ICH. RESULTS A total of 219 CAA patients were included, with an average age of 67.12 ± 9.93. Of all patients, 26.0% were CAA with ICH. Univariate analysis showed that CAA-ICH is associated with carrying more APOE ε2 allele, less lobar cerebral microbleeds (CMBs), cortical superficial siderosis (cSS), lower Fazekas scale, a tendency of gait disorder, and acute onset (P < 0.05). The generalized linear mixed model yielded statistically significant associations between CAA with ICH and carrying the APOE ε2 allele, cSS, the lower number of lobar CMBs, and the lower Fazekas scale (P < 0.05). CONCLUSION It is meaningful to classify CAA with and without ICH, as there may be different mechanisms between the two. CAA with ICH has a susceptibility to carrying APOE ε2, cSS, and a relatively small number of CMBs. Fewer CMBs do not mean lower susceptibility to ICH in CAA. Larger prospective cohort studies are necessary to further clarify these conclusions.
Collapse
Affiliation(s)
- Juanjuan Wu
- Department of Neurology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China
| | - Ziyue Liu
- Department of Neurology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China
| | - Ming Yao
- Department of Neurology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China
| | - Yicheng Zhu
- Department of Neurology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China
| | - Bin Peng
- Department of Neurology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China
| | - Jun Ni
- Department of Neurology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
| |
Collapse
|
25
|
Muir RT, Smith EE. The Spectrum of Cerebral Small Vessel Disease: Emerging Pathophysiologic Constructs and Management Strategies. Neurol Clin 2024; 42:663-688. [PMID: 38937035 DOI: 10.1016/j.ncl.2024.03.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/29/2024]
Abstract
Cerebral small vessel disease (CSVD) is a spectrum of disorders that affect small arterioles, venules, cortical and leptomeningeal vessels, perivascular spaces, and the integrity of neurovascular unit, blood brain barrier, and surrounding glia and neurons. CSVD is an important cause of lacunar ischemic stroke and sporadic hemorrhagic stroke, as well as dementia-which will constitute some of the most substantive population and public health challenges over the next century. This article provides an overview of updated pathophysiologic frameworks of CSVD; discusses common and underappreciated clinical and neuroimaging manifestations of CSVD; and reviews emerging genetic risk factors linked to sporadic CSVD.
Collapse
Affiliation(s)
- Ryan T Muir
- Calgary Stroke Program, Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta T2N 1N4, Canada; Department of Community Health Sciences, University of Calgary, Calgary, Alberta T2N 1N4, Canada; Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta T2N 1N4, Canada
| | - Eric E Smith
- Calgary Stroke Program, Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta T2N 1N4, Canada; Department of Community Health Sciences, University of Calgary, Calgary, Alberta T2N 1N4, Canada; Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta T2N 1N4, Canada.
| |
Collapse
|
26
|
Bonaterra-Pastra A, Solé M, Lope-Piedrafita S, Lucas-Parra M, Castellote L, Marazuela P, Pancorbo O, Rodríguez-Luna D, Hernández-Guillamon M. The presence of circulating human apolipoprotein J reduces the occurrence of cerebral microbleeds in a transgenic mouse model with cerebral amyloid angiopathy. Alzheimers Res Ther 2024; 16:169. [PMID: 39069622 DOI: 10.1186/s13195-024-01541-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2024] [Accepted: 07/22/2024] [Indexed: 07/30/2024]
Abstract
BACKGROUND Cerebral amyloid angiopathy (CAA) is characterized by amyloid-β (Aβ) deposition in cerebral vessels, leading to lobar cerebral microbleeds (CMB) and intracerebral hemorrhages (ICH). Apolipoprotein J (ApoJ) is a multifunctional chaperone related to Aβ aggregation and clearance. Our study investigated the vascular impact of chronic recombinant human Apolipoprotein J (rhApoJ) treatment in a transgenic mouse model of β-amyloidosis with prominent CAA. METHODS Twenty-month-old APP23 C57BL/6 mice received 25 doses of rhApoJ (1 mg/kg) (n = 9) or saline (n = 8) intraperitoneally for 13 weeks, while Wild-type (WT) mice received saline (n = 13). Postmortem brains underwent T2*-weighted magnetic resonance imaging (MRI) to detect hemorrhagic lesions. Aβ levels and distribution, cerebral fibrinogen leakage, brain smooth muscle actin (sma), and plasma matrix metalloproteinases and inflammatory markers were analyzed after treatments. Additionally, plasma samples from 22 patients with lobar ICH were examined to determine the clinical relevance of the preclinical findings. RESULTS rhApoJ-treated APP23 presented fewer cortical CMBs (50-300 μm diameter) (p = 0.012) and cortical larger hemorrhages (> 300 μm) (p = 0.002) than saline-treated mice, independently of Aβ brain levels. MRI-detected hemorrhagic lesions correlated with fibrinogen cerebral extravasation (p = 0.011). Additionally, rhApoJ-treated mice presented higher number of sma-positive vessels than saline-treated mice (p = 0.038). In rhApoJ-treated mice, human ApoJ was detected in plasma and in occasional leptomeningeal vessels, but not in the parenchyma, suggesting that its mechanism of action operates through the periphery. The administration of rhApoJ induced an increase in plasma Groα (p = 0.035) and MIP-1α (p = 0.035) levels, while lower MMP-12 (p = 0.046) levels, compared to the saline-treated group. In acute lobar ICH patients, MMP-12 plasma levels correlated with larger hemorrhage volume (p = 0.040) and irregular ICH shape (p = 0.036). CONCLUSIONS Chronic rhApoJ treatment in aged APP23 mice ameliorated CAA-related neurovascular damage by reducing the occurrence of CMB. We propose that rhApoJ may prevent blood-brain barrier (BBB) leakage and CMB appearance partly through circulating MMP-12 modulation.
Collapse
Affiliation(s)
- Anna Bonaterra-Pastra
- Neurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron, 119-129, Mediterranean Building, 1st floor, lab 106, Barcelona, 08035, Spain
| | - Montse Solé
- Neurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron, 119-129, Mediterranean Building, 1st floor, lab 106, Barcelona, 08035, Spain
- Department of Bioquímica i Biologia Molecular i Institut de Neurociències, Universitat Autònoma de Barcelona, Bellaterra (Barcelona), Spain
| | - Silvia Lope-Piedrafita
- Nuclear Magnetic Resonance Service, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
| | - Maria Lucas-Parra
- Neurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron, 119-129, Mediterranean Building, 1st floor, lab 106, Barcelona, 08035, Spain
| | - Laura Castellote
- Department of Clinical Biochemistry, Clinical Laboratories, Vall d'Hebron University Hospital, Barcelona, Spain
| | - Paula Marazuela
- Neurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron, 119-129, Mediterranean Building, 1st floor, lab 106, Barcelona, 08035, Spain
| | - Olalla Pancorbo
- Stroke Research Group, Vall d'Hebron Research Institute, Barcelona, Spain
| | | | - Mar Hernández-Guillamon
- Neurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron, 119-129, Mediterranean Building, 1st floor, lab 106, Barcelona, 08035, Spain.
| |
Collapse
|
27
|
Jun HS, Yang K, Kim J, Jeon JP, Kim SJ, Ahn JH, Lee SJ, Choi HJ, Chang IB, Park JJ, Rhim JK, Jin SC, Cho SM, Joo SP, Sheen SH, Lee SH. Telemedicine Protocols for the Management of Patients with Acute Spontaneous Intracerebral Hemorrhage in Rural and Medically Underserved Areas in Gangwon State : Recommendations for Doctors with Less Expertise at Local Emergency Rooms. J Korean Neurosurg Soc 2024; 67:385-396. [PMID: 37901932 PMCID: PMC11220410 DOI: 10.3340/jkns.2023.0199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2023] [Revised: 10/16/2023] [Accepted: 10/23/2023] [Indexed: 10/31/2023] Open
Abstract
Previously, we reported the concept of a cloud-based telemedicine platform for patients with intracerebral hemorrhage (ICH) at local emergency rooms in rural and medically underserved areas in Gangwon state by combining artificial intelligence and remote consultation with a neurosurgeon. Developing a telemedicine ICH treatment protocol exclusively for doctors with less ICH expertise working in emergency rooms should be part of establishing this system. Difficulties arise in providing appropriate early treatment for ICH in rural and underserved areas before the patient is transferred to a nearby hub hospital with stroke specialists. This has been an unmet medical need for decade. The available reporting ICH guidelines are realistically possible in university hospitals with a well-equipped infrastructure. However, it is very difficult for doctors inexperienced with ICH treatment to appropriately select and deliver ICH treatment based on the guidelines. To address these issues, we developed an ICH telemedicine protocol. Neurosurgeons from four university hospitals in Gangwon state first wrote the guidelines, and professors with extensive ICH expertise across the country revised them. Guidelines and recommendations for ICH management were described as simply as possible to allow more doctors to use them easily. We hope that our effort in developing the telemedicine protocols will ultimately improve the quality of ICH treatment in local emergency rooms in rural and underserved areas in Gangwon state.
Collapse
Affiliation(s)
- Hyo Sub Jun
- Department of Neurosurgery, Kangwon National University Hospital, Chuncheon, Korea
| | - Kuhyun Yang
- Department of Neurosurgery, Gangneung Asan Hospital, Gangneung, Korea
| | - Jongyeon Kim
- Department of Neurosurgery, Yonsei University Wonju College of Medicine, Wonju, Korea
| | - Jin Pyeong Jeon
- Department of Neurosurgery, Hallym University College of Medicine, Chuncheon, Korea
| | - Sun Jeong Kim
- Department of Convergence Software, Hallym University, Chuncheon, Korea
| | - Jun Hyong Ahn
- Department of Neurosurgery, Kangwon National University Hospital, Chuncheon, Korea
| | - Seung Jin Lee
- Department of Neurosurgery, Kangwon National University Hospital, Chuncheon, Korea
| | - Hyuk Jai Choi
- Department of Neurosurgery, Hallym University College of Medicine, Chuncheon, Korea
| | - In Bok Chang
- Department of Neurosurgery, Hallym University College of Medicine, Chuncheon, Korea
| | - Jeong Jin Park
- Department of Neurology, Konkuk University Medical Center, Seoul, Korea
| | - Jong-Kook Rhim
- Department of Neurosurgery, Jeju National University College of Medicine, Jeju, Korea
| | - Sung-Chul Jin
- Department of Neurosurgery, Inje University Haeundae Paik Hospital, Busan, Korea
| | - Sung Min Cho
- Department of Neurosurgery, Yonsei University Wonju College of Medicine, Wonju, Korea
| | - Sung-Pil Joo
- Department of Neurosurgery, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea
| | - Seung Hun Sheen
- Department of Neurosurgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea
| | - Sang Hyung Lee
- Department of Neurosurgery, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea
| | - on behalf of the Gangwon State Neurosurgery Consortium
- Department of Neurosurgery, Kangwon National University Hospital, Chuncheon, Korea
- Department of Neurosurgery, Gangneung Asan Hospital, Gangneung, Korea
- Department of Neurosurgery, Yonsei University Wonju College of Medicine, Wonju, Korea
- Department of Neurosurgery, Hallym University College of Medicine, Chuncheon, Korea
- Department of Convergence Software, Hallym University, Chuncheon, Korea
- Department of Neurology, Konkuk University Medical Center, Seoul, Korea
- Department of Neurosurgery, Jeju National University College of Medicine, Jeju, Korea
- Department of Neurosurgery, Inje University Haeundae Paik Hospital, Busan, Korea
- Department of Neurosurgery, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea
- Department of Neurosurgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea
- Department of Neurosurgery, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea
| |
Collapse
|
28
|
Hilkens NA, Casolla B, Leung TW, de Leeuw FE. Stroke. Lancet 2024; 403:2820-2836. [PMID: 38759664 DOI: 10.1016/s0140-6736(24)00642-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/08/2024] [Revised: 03/19/2024] [Accepted: 03/26/2024] [Indexed: 05/19/2024]
Abstract
Stroke affects up to one in five people during their lifetime in some high-income countries, and up to almost one in two in low-income countries. Globally, it is the second leading cause of death. Clinically, the disease is characterised by sudden neurological deficits. Vascular aetiologies contribute to the most common causes of ischaemic stroke, including large artery disease, cardioembolism, and small vessel disease. Small vessel disease is also the most frequent cause of intracerebral haemorrhage, followed by macrovascular causes. For acute ischaemic stroke, multimodal CT or MRI reveal infarct core, ischaemic penumbra, and site of vascular occlusion. For intracerebral haemorrhage, neuroimaging identifies early radiological markers of haematoma expansion and probable underlying cause. For intravenous thrombolysis in ischaemic stroke, tenecteplase is now a safe and effective alternative to alteplase. In patients with strokes caused by large vessel occlusion, the indications for endovascular thrombectomy have been extended to include larger core infarcts and basilar artery occlusion, and the treatment time window has increased to up to 24 h from stroke onset. Regarding intracerebral haemorrhage, prompt delivery of bundled care consisting of immediate anticoagulation reversal, simultaneous blood pressure lowering, and prespecified stroke unit protocols can improve clinical outcomes. Guided by underlying stroke mechanisms, secondary prevention encompasses pharmacological, vascular, or endovascular interventions and lifestyle modifications.
Collapse
Affiliation(s)
- Nina A Hilkens
- Department of Neurology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, Netherlands
| | - Barbara Casolla
- Université Nice Cote d'Azur UR2CA-URRIS, Stroke Unit, CHU Pasteur 2, Nice, France
| | - Thomas W Leung
- Division of Neurology, Department of Medicine and Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China
| | - Frank-Erik de Leeuw
- Department of Neurology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, Netherlands.
| |
Collapse
|
29
|
Huang B, Chen A, Sun Y, He Q. The Role of Aging in Intracerebral Hemorrhage. Brain Sci 2024; 14:613. [PMID: 38928613 PMCID: PMC11201415 DOI: 10.3390/brainsci14060613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2024] [Revised: 06/10/2024] [Accepted: 06/17/2024] [Indexed: 06/28/2024] Open
Abstract
Intracerebral hemorrhage (ICH) is the cerebrovascular disease with the highest disability and mortality rates, causing severe damage to the health of patients and imposing a significant socioeconomic burden. Aging stands as a foremost risk factor for ICH, with a significant escalation in ICH incidence within the elderly demographic, highlighting a close association between ICH and aging. In recent years, with the acceleration of the "aging society" trend, exploring the intricate relationship between aging and ICH has become increasingly urgent and worthy of in-depth attention. We have summarized the characteristics of ICH in the elderly, reviewing how aging influences the onset and development of ICH by examining its etiology and the mechanisms of damage via ICH. Additionally, we explored the potential impacts of ICH on accelerated aging, including its effects on cognitive abilities, quality of life, and lifespan. This review aims to reveal the connection between aging and ICH, providing new ideas and insights for future ICH research.
Collapse
Affiliation(s)
| | | | | | - Quanwei He
- Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
| |
Collapse
|
30
|
Morotti A, Nawabi J, Pilotto A, Toffali M, Busto G, Mazzacane F, Cavallini A, Laudisi M, Gentile L, Viola MM, Schlunk F, Bartolini D, Paciaroni M, Magoni M, Bassi C, Simonetti L, Fainardi E, Casetta I, Zini A, Padovani A. Functional outcome improvement from 3 to 12 months after intracerebral hemorrhage. Eur Stroke J 2024; 9:391-397. [PMID: 38183279 PMCID: PMC11318429 DOI: 10.1177/23969873231222782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Accepted: 12/09/2023] [Indexed: 01/08/2024] Open
Abstract
INTRODUCTION Most intracerebral hemorrhage (ICH) trials assessed outcome at 3 months but the recovery trajectory of ICH survivors may continue up to 1 year after the index event. We aimed to describe the predictors of functional outcome improvement from 3 to 12 months after ICH. MATERIALS AND METHODS Retrospective analysis of patients admitted to six European Stroke Centers for supratentorial ICH. Functional outcome was measured with the modified Rankin Scale (mRS) at 3 and 12 months. Predictors of functional outcome improvement were explored with binary logistic regression. RESULTS We included 703 patients, of whom 245 (34.9%) died within 3 months. Among survivors, 131 (28.6%) had an mRS improvement, 78 (17.0%) had a worse mRS and 249 (54.4%) had a stable functional status at 12 months. Older age and the presence of baseline disability (defined as pre-stroke mRS > 1), were associated with lower odds of functional outcome improvement (Odds Ratio (OR) 0.98 per year increase, 95% Confidence Interval (CI) 0.96-1.00, p = 0.017 and OR 0.45, 95% CI 0.25-0.81, p = 0.008 respectively). Conversely, deep ICH location increased the probability of long term mRS improvement (OR 1.67, 95% CI, 1.07-2.61, p = 0.023). Patients with mild-moderate disability at 3 months (mRS 2-3) had the highest odds of improvement at 12 months (OR 8.76, 95% CI 3.68-20.86, p < 0.001). DISCUSSION AND CONCLUSION Long term recovery is common after ICH and associated with age, baseline functional status, mRS at 3 months and hematoma location. Our findings might inform future trials and improve long-term prognostication in clinical practice.
Collapse
Affiliation(s)
- Andrea Morotti
- Department of Continuity of Care and Frailty, Neurology Unit, ASST-Spedali Civili, Brescia, Italy
- Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy
| | - Jawed Nawabi
- Department of Neuroradiology, Charité - Universitätsmedizin Berlin, Campus Mitte, Humboldt-Universität zu Berlin, Freie Universität Berlin, Berlin Institute of Health, Berlin, Germany
- Berlin Institute of Health (BIH), BIH Biomedical Innovation Academy, Berlin, Germany
| | - Andrea Pilotto
- Department of Continuity of Care and Frailty, Neurology Unit, ASST-Spedali Civili, Brescia, Italy
- Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy
| | - Maddalena Toffali
- Department of Continuity of Care and Frailty, Neurology Unit, ASST-Spedali Civili, Brescia, Italy
- Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy
| | - Giorgio Busto
- Department of Experimental and Clinical Biomedical Sciences, Neuroradiology Unit, University of Firenze, AOU Careggi, Firenze, Italy
| | - Federico Mazzacane
- U.C. Malattie Cerebrovascolari e Stroke Unit, IRCCS Fondazione Mondino, Pavia, Italia
| | - Anna Cavallini
- U.C. Malattie Cerebrovascolari e Stroke Unit, IRCCS Fondazione Mondino, Pavia, Italia
| | - Michele Laudisi
- Clinica Neurologica, Dipartimento di Scienze Biomediche e Chirurgico Specialistiche, Università degli studi di Ferrara, Ospedale Universitario S. Anna, Ferrara, Italia
| | - Luana Gentile
- IRCCS Istituto delle Scienze Neurologiche di Bologna,UOC Neurologia e Rete Stroke Metropolitana, Ospedale Maggiore, Bologna, Italia
| | - Maria Maddalena Viola
- IRCCS Istituto delle Scienze Neurologiche di Bologna,UOC Neurologia e Rete Stroke Metropolitana, Ospedale Maggiore, Bologna, Italia
| | - Frieder Schlunk
- Department of Neuroradiology, Medical Centre, University of Freiburg, Freiburg, Germany
| | - Diletta Bartolini
- Cardiovascular and Emergency Medicine, Stroke Unit, University of Perugia/Azienda Ospedaliera Santa Maria Della Misericordia, Perugia, Italy
| | - Maurizio Paciaroni
- Cardiovascular and Emergency Medicine, Stroke Unit, University of Perugia/Azienda Ospedaliera Santa Maria Della Misericordia, Perugia, Italy
| | - Mauro Magoni
- Stroke Unit, Neurologia Vascolare, ASST Spedali Civili di Brescia, Brescia, Italy
| | - Chiara Bassi
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
| | - Luigi Simonetti
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Neuroradiology Unit, Maggiore Hospital, Bologna, Italy
| | - Enrico Fainardi
- Department of Experimental and Clinical Biomedical Sciences, Neuroradiology Unit, University of Firenze, AOU Careggi, Firenze, Italy
| | - Ilaria Casetta
- Clinica Neurologica, Dipartimento di Scienze Biomediche e Chirurgico Specialistiche, Università degli studi di Ferrara, Ospedale Universitario S. Anna, Ferrara, Italia
| | - Andrea Zini
- IRCCS Istituto delle Scienze Neurologiche di Bologna,UOC Neurologia e Rete Stroke Metropolitana, Ospedale Maggiore, Bologna, Italia
| | - Alessandro Padovani
- Department of Continuity of Care and Frailty, Neurology Unit, ASST-Spedali Civili, Brescia, Italy
- Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy
| |
Collapse
|
31
|
Xu M, Zhu Y, Song X, Zhong X, Yu X, Wang D, Cheng Y, Tao W, Wu B, Liu M. Pathological Changes of Small Vessel Disease in Intracerebral Hemorrhage: a Systematic Review and Meta-analysis. Transl Stroke Res 2024; 15:533-544. [PMID: 37280502 PMCID: PMC11106194 DOI: 10.1007/s12975-023-01154-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Revised: 04/05/2023] [Accepted: 04/13/2023] [Indexed: 06/08/2023]
Abstract
In intracerebral hemorrhage (ICH) with pathology-proven etiology, we performed a systematic review and meta-analysis to elucidate the association between cerebral amyloid angiopathy (CAA) and arteriolosclerosis, and directly compared MRI and pathological changes of markers of cerebral small vessel disease (CSVD). Studies enrolling primary ICH who had received an etiological diagnosis through biopsy or autopsy were searched using Ovid MEDLINE, PubMed, and Web of Science from inception to June 8, 2022. We extracted pathological changes of CSVD for each patient whenever available. Patients were grouped into CAA + arteriolosclerosis, strict CAA, and strict arteriolosclerosis subgroups. Of 4155 studies identified, 28 studies with 456 ICH patients were included. The frequency of lobar ICH (p<0.001) and total microbleed number (p=0.015) differed among patients with CAA + arteriolosclerosis, strict CAA, and strict arteriolosclerosis. Concerning pathology, severe CAA was associated with arteriolosclerosis (OR 6.067, 95% CI 1.107-33.238, p=0.038), although this association was not statistically significant after adjusting for age and sex. Additionally, the total microbleed number (median 15 vs. 0, p=0.006) was higher in ICH patients with CAA evidence than those without CAA. The pathology of CSVD imaging markers was mostly investigated in CAA-ICH. There was inconsistency concerning CAA severity surrounding microbleeds. Small diffusion-weighted imaging lesions could be matched to acute microinfarct histopathologically. Studies that directly correlated MRI and pathology of lacunes, enlarged perivascular spaces, and atrophy were scarce. Arteriolosclerosis might be associated with severe CAA. The pathological changes of CSVD markers by ICH etiology are needed to be investigated further.
Collapse
Affiliation(s)
- Mangmang Xu
- Department of Neurology, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan Province, China
- Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Sichuan Province, Chengdu, China
| | - Yuyi Zhu
- Department of Neurology, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan Province, China
- Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Sichuan Province, Chengdu, China
| | - Xindi Song
- Department of Neurology, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan Province, China
- Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Sichuan Province, Chengdu, China
| | - Xuelian Zhong
- West China School of Nursing, Sichuan University/West China Hospital of Sichuan University, Chengdu, Sichuan Province, China
| | - Xinxin Yu
- Department of Orthodontics, ChengDu Dental Hospital, Chengdu, Sichuan Province, China
| | - Deren Wang
- Department of Neurology, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan Province, China
- Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Sichuan Province, Chengdu, China
| | - Yajun Cheng
- Department of Neurology, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan Province, China
- Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Sichuan Province, Chengdu, China
| | - Wendan Tao
- Department of Neurology, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan Province, China
- Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Sichuan Province, Chengdu, China
| | - Bo Wu
- Department of Neurology, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan Province, China.
- Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Sichuan Province, Chengdu, China.
| | - Ming Liu
- Department of Neurology, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, Sichuan Province, China.
- Center of Cerebrovascular Diseases, West China Hospital, Sichuan University, Sichuan Province, Chengdu, China.
| |
Collapse
|
32
|
Jia S, Liu X, Qu H, Jia X. Observation of the Therapeutic Effect of Dual Antiplatelet Therapy with Aspirin and Clopidogrel on the Incidence, Characteristics, and Outcome in Acute Ischemic Stroke Patients with Cerebral Microbleeds at a Teaching Hospital, China. Int J Gen Med 2024; 17:2327-2336. [PMID: 38803551 PMCID: PMC11128718 DOI: 10.2147/ijgm.s459323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2024] [Accepted: 04/30/2024] [Indexed: 05/29/2024] Open
Abstract
Background Cerebral microbleeds (CMBs) are an important risk factor for stroke recurrence and prognosis. However, there is no consensus on the safety of antiplatelet therapy in patients with ischemic stroke and CMBs. Objective This study aimed to observe the effects of dual antiplatelet therapy with aspirin and clopidogrel on bleeding conversion in patients with different degrees of CMBs. Materials and Methods An observational retrospective study was conducted on 160 patients with acute mild ischemic stroke admitted to the Stroke Center, Affiliated Hospital of Beihua University between March 2021 and December 2022. Patients were divided into the CMBs and non-CMB groups. The CMB group was then divided into the low, medium and high-risk groups. In two groups, all patients were administered dual antiplatelet therapy (aspirin 100 mg and clopidogrel 75 mg orally once a day for 21 days according to the Chinese Stroke Guidelines of 2018), and no other anticoagulant or antiplatelet drugs were administered during the treatment period. Head CT, National Institutes of Health Stroke Scale(NIHSS) and modified Rankin Scale (mRS) score were re-checked, and the number of bleeding conversions was calculated at 21 days. Results Five patients in the CMB group had intracranial hemorrhage (5/116, 4.3%), while no intracranial hemorrhage was observed in the non-CMB group. There were no differences in the conversion rate of cerebral hemorrhage, NIHSS score, or mRS score between two groups after dual antiplatelet therapy (p>0.05). The conversion rate of cerebral hemorrhage in the high-risk group was higher than that in the non-CMB group (p<0.05), but the NIHSS and mRS score showed no difference between the high-risk and non-CMB groups (p>0.05). Conclusion Dual antiplatelet therapy with aspirin and clopidogrel does not significantly increase the risk of bleeding transformation; however, it improves neurological recovery or long-term prognosis in patients with acute ischemic cerebral stroke complicated by low-risk and middle-risk CMBs.
Collapse
Affiliation(s)
- Shaojie Jia
- Stroke Center, Affiliated Hospital, Beihua University, Jilin, 132011, People’s Republic of China
- Department of Orthopedics, Affiliated Hospital, Beihua University, Jilin, 132011, People’s Republic of China
| | - Xin Liu
- Department of Neurology II, Affiliated Hospital, Beihua University, Jilin, 132011, People’s Republic of China
| | - Hongyan Qu
- Department of Neurology II, Affiliated Hospital, Beihua University, Jilin, 132011, People’s Republic of China
| | - Xiaojing Jia
- Stroke Center, Affiliated Hospital, Beihua University, Jilin, 132011, People’s Republic of China
- Department of Neurology II, Affiliated Hospital, Beihua University, Jilin, 132011, People’s Republic of China
| |
Collapse
|
33
|
Wu X, Chen Z, Chen Q, Lin C, Zheng X, Yuan B. Nrdp1-mediated Macrophage Phenotypic Regulation Promotes Functional Recovery in Mice with Mild Neurological Impairment after Intracerebral Hemorrhage. Neuroscience 2024; 545:16-30. [PMID: 38431041 DOI: 10.1016/j.neuroscience.2024.02.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Revised: 02/16/2024] [Accepted: 02/26/2024] [Indexed: 03/05/2024]
Abstract
Neuregulin receptor degradation protein 1 (Nrdp1) is a ring finger E3 ubiquitin ligase involved in some inflammation through ubiquitination, including macrophage polarization following cerebral hemorrhage. However, there is limited understanding regarding the mechanisms through which Nrdp1 modulates macrophage polarization and the potential impact of this modulation on neurological function. Using stereotactic injection and adenoviral transfection techniques, the corresponding animal models were constructed through injecting adenovirus, saline, or blood into the mouse striatum at different periods of time in this research. The alteration in the ratio of various M1/M2 phenotype-associated markers (e.g., CD86, CD206, IL-6, IL-10, etc.) was evaluated through immunohistochemistry, immunofluorescence, western blotting, and elisa assays. Additionally, neurological function scores and behavioral tests were utilized to evaluate changes in neurological function in mice after cerebral hemorrhage. Our results show that overexpression of Nrdp1 promotes the expression of a variety of M2 macrophage-associated markers and enhance transcriptional activity of arginase-1 (Arg1) protein through ubiquitination for early regulation M2 macrophage polarization. Additionally, Nrdp1 promotes hematoma absorption, increases IL-10 expression, inhibits inducible nitric oxide synthase (iNOS), IL-6, and TNF-α production, alleviates neurological impairment and brain edema, and accelerates functional recovery. These findings suggest that modulating macrophage polarization through Nrdp1 could be a therapeutic strategy for neurofunctional impairment in cerebral hemorrhage.
Collapse
Affiliation(s)
- Xiyao Wu
- Department of Neurosurgery, 900TH Hospital of Joint Logistics Support Force, Fuzhou, Fujian 350000, China
| | - Zhiling Chen
- Department of Neurosurgery, 900TH Hospital of Joint Logistics Support Force, Fuzhou, Fujian 350000, China
| | - Qiuming Chen
- Department of Neurosurgery, 900TH Hospital of Joint Logistics Support Force, Fuzhou, Fujian 350000, China
| | - Chuangan Lin
- Department of Neurosurgery, 900TH Hospital of Joint Logistics Support Force, Fuzhou, Fujian 350000, China
| | - Xiangrong Zheng
- Department of Ophthalmology, 900TH Hospital of Joint Logistics Support Force, Fuzhou, Fujian 350000, China
| | - Bangqing Yuan
- Department of Neurosurgery, 900TH Hospital of Joint Logistics Support Force, Fuzhou, Fujian 350000, China; Fuzong Clinical Medical College of Fujian Medical University (900TH Hospital), Fuzhou, Fujian 350000, China.
| |
Collapse
|
34
|
Greenberg SM, van Veluw SJ. Cerebral Amyloid Angiopathy. Stroke 2024; 55:1409-1411. [PMID: 38269538 DOI: 10.1161/strokeaha.124.044293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2024]
Affiliation(s)
- Steven M Greenberg
- J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston (S.M.G., S.J.v.V.)
| | - Susanne J van Veluw
- J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston (S.M.G., S.J.v.V.)
- Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown (S.J.v.V.)
| |
Collapse
|
35
|
Jali V, Mishra NK, Vibha D, Dwivedi SN, Srivastava AK, Verma V, Kumar A, Nair P, Prasad K. Prevalence and Risk Factors of Cerebral Microbleeds in Community-Dwelling Adults in Urban Delhi. Ann Indian Acad Neurol 2024; 27:236-243. [PMID: 38902872 PMCID: PMC11232832 DOI: 10.4103/aian.aian_71_24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2024] [Revised: 04/26/2024] [Accepted: 05/03/2024] [Indexed: 06/22/2024] Open
Abstract
BACKGROUND Several observational studies have reported the prevalence of cerebral microbleeds (CMBs) and their risk factors in an elderly population. Any information in this regard is currently lacking from India. Aim of this study was to estimate the prevalence, risk factors of CMBs, and association with cognition in an Indian urban population aged 50 years and above. METHODS Household surveys were conducted as part of ongoing Longitudinal Cognition and Aging Research on Population of the National Capital Region (LoCARPoN) study in areas of urban Delhi. Magnetic resonance imaging of the brain was performed in 2599 participants. Using standard neuropsychological battery, mean Z-scores for each domain (memory, executive, information) were derived. Binary and stepwise logistic regression models were used to determine associated risk factors for the presence of CMB and its association with cognitive domains. RESULTS The prevalence of CMBs was 14.42% (95% confidence interval [CI]: 13.06-15.73). Of these, 203 (7.81%) participants had single CMBs and 172 (6.61%) had multiple microbleeds (≥2). Higher prevalence was observed in older age (60-70 years: odds ratio [OR]: 1.25 [95% CI: 0.93-1.67]; 70-80 years: OR: 2.05 [95% CI: 1.48-2.84]; ≥80 years: OR: 3.27 [95% CI: 1.97-5.44]) compared to individuals in the age group 50-60 years. History of stroke (OR: 2.97 [95% CI: 1.56-5.66]), hypertension (OR: 1.36 [95% CI: 1.05-1.75]), and smoking (OR: 1.43 [95% CI: 1.11-1.85]) was associated with at least one CMB. Multiple CMBs were associated with worse scores in memory and executive domains. CONCLUSION Older age, hypertension, history of stroke, and history of smoking emerged as important risk factors for the presence of multiple CMBs. Follow-up study is required to determine implications of CMBs.
Collapse
Affiliation(s)
- Vidishaa Jali
- Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
| | - Nalini K Mishra
- Department of Neuroimaging and Interventional Neuroradiology, All India Institute of Medical Sciences, New Delhi, India
| | - Deepti Vibha
- Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
| | - Sada N Dwivedi
- Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India
- Department of Community Medicine, International Centre for Health Research (ICHR), RD Gardi Medical College, Madhya Pradesh, India
| | - Achal K Srivastava
- Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
| | - Vivek Verma
- Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
- Department of Statistics, Assam University, Silchar, Assam, India
| | - Amit Kumar
- Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
- Department of Lab Medicine, R.I.M.S. Ranchi, Jharkhand, India
| | - Pallavi Nair
- Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
| | - Kameshwar Prasad
- Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
| |
Collapse
|
36
|
Nagaraja N, Ballur Narayana Reddy V. Prevalence of Concomitant Neurological Disorders and Long-Term Outcome of Patients Hospitalized for Intracerebral Hemorrhage with Versus without Cerebral Amyloid Angiopathy. Neurocrit Care 2024; 40:486-494. [PMID: 37258986 DOI: 10.1007/s12028-023-01753-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2022] [Accepted: 05/10/2023] [Indexed: 06/02/2023]
Abstract
BACKGROUND Patients with intracerebral hemorrhage (ICH) related to cerebral amyloid angiopathy (CAA) are at increased risk of developing epilepsy and cognitive disorders such as Alzheimer's disease (AD), mild cognitive impairment (MCI), and vascular dementia. In a retrospective cohort observation study of patients hospitalized for ICH with CAA versus ICH without CAA, we evaluated the prevalence of neurological comorbidities at admission and the risk of new diagnosis of epilepsy, relevant cognitive disorders, and mortality at 1 year. METHODS In the TriNetX health research network, adult patients aged ≥ 55 years hospitalized with a diagnosis of ICH were stratified based on presence or absence of concomitant CAA diagnosis. Demographics and medical comorbidities were compared by using χ2 test and Student's t-test. After 1:1 propensity score matching, 1-year survival was assessed with Kaplan-Meier curves. The 1-year risk of new diagnosis of epilepsy, AD, MCI, vascular dementia, and dementia unspecified was assessed with Cox proportional hazards estimate. RESULTS The study included a total of 1757 patients with ICH and CAA and 53,364 patients with ICH without CAA. Patients with CAA were older compared with those without CAA (74.1 ± 7.5 vs. 69.8 ± 8.8 years, p ≤ 0.001). Compared with ICH without CAA, patients with ICH and CAA had higher baseline prevalence of cerebral infarction (30% vs. 20%), nontraumatic ICH (36% vs. 7%), nontraumatic subarachnoid hemorrhage (14% vs. 5%), epilepsy (11% vs. 6%), and AD (5% vs. 2%) with significance at p < 0.001. After propensity score matching, a total of 1746 patients were included in both cohorts. In the matched cohorts, compared with patients with ICH without CAA, patients with ICH and CAA had lower 1-year all-cause mortality (479 [27%] vs. 563 [32%]; hazard ratio [HR] 0.80; 95% confidence interval [CI] 0.71-0.90) and higher risk of new diagnosis of epilepsy (280 [18%] vs. 167 [11%]; HR 1.70; 95% CI 1.40-2.06), AD (101 [6%] vs. 38 [2%]; HR 2.62; 95% CI 1.80-3.80), MCI (85 [5%] vs. 35 [2%]; HR 2.39; 95% CI 1.61-3.54), vascular dementia (117 [7%] vs. 60 [4%]; HR 1.92; 95% CI 1.41-2.62), and dementia unspecified (245 [16%] vs. 150 [9%]; HR 1.70; 95% CI 1.39-2.08). CONCLUSIONS Among patients admitted for ICH, patients with CAA have lower mortality but have 2-3 times more risk of diagnosis of epilepsy and dementia at 1 year, compared with those without CAA.
Collapse
Affiliation(s)
- Nandakumar Nagaraja
- Department of Neurology, Milton S. Hershey Medical Center, Penn State College of Medicine, 30 Hope Drive EC037, Hershey, PA, 17033, USA.
| | - Varalakshmi Ballur Narayana Reddy
- Department of Neurology, Milton S. Hershey Medical Center, Penn State College of Medicine, 30 Hope Drive EC037, Hershey, PA, 17033, USA
| |
Collapse
|
37
|
Zhan Z, Fu F, Zhang W, Cheng Z. Prevalence, Risk Factors, and Clinical Outcomes of New Cerebral Microbleeds After Intravenous Thrombolysis in Acute Ischemic Stroke: a Systematic Review and Meta-analysis. Clin Neuroradiol 2024; 34:209-218. [PMID: 37857916 DOI: 10.1007/s00062-023-01357-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Accepted: 09/26/2023] [Indexed: 10/21/2023]
Abstract
BACKGROUND Cerebral microbleeds (CMBs) are common in the elderly population, and are associated with an increased risk of stroke and dementia. An acute ischemic stroke event can make CMBs develop rapidly. However, the progression of CMBs after intravenous thrombolysis is not well understood. METHODS Following a previously registered protocol, PubMed, Web of Science, and Embase databases were systematically searched to identify relevant literature up to August 2022. Cohort studies that reported new CMBs in patients with acute ischemic stroke undergoing intravenous thrombolysis were included. Random effects models were used to calculate the pooled estimates. RESULTS Seven studies with 1079 patients were included in the meta-analysis. The pooled new CMBs prevalence was 7.6% (95% CI 3.9-14.3%) and 63.6% new CMBs were located in the cerebral lobes. Compared with patients without new CMBs, those with new CMBs were older, had a higher proportion of hypertension, and had higher systolic blood pressure and baseline CMBs burden. The presence of new CMBs increased the likelihood of remote intracerebral hemorrhage (OR 28.75, 95% CI 8.58-96.38) and symptomatic intracerebral hemorrhage (OR 15.49, 95% CI 3.21-74.73) but was not related to functional outcomes or hemorrhagic transformation. CONCLUSIONS The prevalence of new CMBs after intravenous thrombolysis was approximately 7.6%. The presence of new CMBs is associated with remote and symptomatic intracerebral hemorrhage following intravenous thrombolysis. Considering the potential long-term adverse effects of CMBs progression, patients at a high risk of developing new CMBs should be identified based on potential risk factors.
Collapse
Affiliation(s)
- Zhenxiang Zhan
- Department of Neurology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China
| | - Fangwang Fu
- Department of Neurology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China
| | - Wenyuan Zhang
- Department of Neurology, Affiliated Yueqing Hospital, Wenzhou Medical University, Yueqing, China
| | - Zicheng Cheng
- Department of Neurology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
| |
Collapse
|
38
|
Liu YT, Lei CY, Zhong LM. Research Advancements on the Correlation Between Spontaneous Intracerebral Hemorrhage of Different Etiologies and Imaging Markers of Cerebral Small Vessel Disease. Neuropsychiatr Dis Treat 2024; 20:307-316. [PMID: 38405425 PMCID: PMC10893791 DOI: 10.2147/ndt.s442334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Accepted: 01/24/2024] [Indexed: 02/27/2024] Open
Abstract
Objective The purpose of this review is to identify the correlation between ICH and CSVD imaging markers under SMASH-U classification by searching and analyzing a large number of literatures in recent years, laying a theoretical foundation for future clinical research. At the same time, by collecting clinical data to evaluate patient prognosis, analyzing whether there are differences or supplements between clinical trial conclusions and previous theories, and ultimately guiding clinical diagnosis and treatment through the analysis of imaging biomarkers. Methods In this review, by searching CNKI, Web of Science, PubMed, FMRS and other databases, the use of "spontaneous intracerebral hemorrhage", "hypertensive hemorrhagic cerebral small vessel disease", "cerebral small vessel disease imaging", "Based cerebral small vessel diseases", "SMASH the -u classification" and their Chinese equivalents for the main search term. We focused on reading and analyzing hundreds of relevant literatures in the last decade from August 2011 to April 2020, and also included some earlier literatures with conceptual data sources. After screening and ranking the degree of relevance to this study, sixty of them were cited for analysis and elaboration. Results In patients with ICH, the number of cerebral microbleeds in lobes, basal ganglia, and the deep brain is positively correlated with ICH volume and independently correlated with neurological functional outcomes; white matter hyperintensity severity is positively correlated with ICH recurrence risk; multiple lacunar infarction independently predict the risk of ICH; severe brain atrophy is an independent risk factor for a poor prognosis in the long term in patients diagnosed with ICH; and the number of enlarged perivascular spaces is correlated with ICH recurrence. However, small subcortical infarct and ICH are the subject of few studies. Higher CSVD scores are independently associated with functional outcomes at 90 days in patients diagnosed with ICH.
Collapse
Affiliation(s)
- Yu-Tong Liu
- Department of Neurology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, People’s Republic of China
| | - Chun-Yan Lei
- Department of Neurology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, People’s Republic of China
| | - Lian-Mei Zhong
- Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, People’s Republic of China
| |
Collapse
|
39
|
Moliner-Abós C, Albertí-Vall B, Millan-Álvarez X, Camps-Renom P, Guasch-Jiménez M, Asmarats-Serra L, Lambea-Gil Á, Ezcurra-Díaz G, Arzamendi-Aizpurua D, Martí-Fàbregas J. Left atrial appendage occlusion in patients with spontaneous intracerebral hemorrhage: An observational study. J Stroke Cerebrovasc Dis 2024; 33:107481. [PMID: 38064973 DOI: 10.1016/j.jstrokecerebrovasdis.2023.107481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Revised: 10/20/2023] [Accepted: 11/08/2023] [Indexed: 01/23/2024] Open
Abstract
BACKGROUND Patients with atrial fibrillation (AF) and intracerebral hemorrhage (ICH) are at high risk of ischemic and recurrent bleeding events. Therefore, the decision of restarting or avoiding anticoagulation is challenging. Left atrial appendage occlusion (LAAO) is an alternative for these patients. However, few data are available about safety of early LAAO and factors associated with ischemic stroke and ICH recurrence. METHODS A unicentric, observational, retrospective study including all patients with AF and a previous ICH who underwent LAAO. We analyzed baseline clinical and neuroimaging characteristics, procedural outcomes, post-procedural therapies and long-term follow-up. RESULTS Forty patients were included, whose mean age was 76.6 ±7.6 years and 73 % were men. In patients in whom a Magnetic Resonance (MR) was performed (n=22, 55 %), cortical microbleeds were detected in 15 (68 %) and cortical superficial siderosis in one patient. The procedure was successful and safe in 100 % of the patients and it was performed within 30 days of the ICH in 37 % of them. After a median follow up of 46.2 months [26-69], intracranial hemorrhage (ICrH) recurrence occurred in 6 patients (5 ICH and 1 subdural hematoma -SDH-) and the index ICH was lobar in all of them. Ischemic events were significantly lower than expected according to the CHA2DS2-VASc score (7.5 % vs. 16.6 %, p=0.048) and bleeding events were similar to expected by the HAS-BLED score (20 % vs 23.4 %, p=0.63). CONCLUSIONS In patients with ICH and AF, early LAAO was found to be safe and associated with a reduction in ischemic stroke. However, recurrent ICH risk remains high, and it appears to be mainly driven by cerebral amyloid angiopathy.
Collapse
Affiliation(s)
- Carlos Moliner-Abós
- Cardiology Department, Hospital de la Santa Creu i Sant Pau. Carrer St. Antoni M. Claret 89, Barcelona 08025, Spain
| | - Blanca Albertí-Vall
- Neurology Department, Hospital de la Santa Creu i Sant Pau. Carrer St. Antoni M. Claret 89, Barcelona 08025, Spain
| | - Xavier Millan-Álvarez
- Cardiology Department, Hospital de la Santa Creu i Sant Pau. Carrer St. Antoni M. Claret 89, Barcelona 08025, Spain
| | - Pol Camps-Renom
- Neurology Department, Hospital de la Santa Creu i Sant Pau. Carrer St. Antoni M. Claret 89, Barcelona 08025, Spain.
| | - Marina Guasch-Jiménez
- Neurology Department, Hospital de la Santa Creu i Sant Pau. Carrer St. Antoni M. Claret 89, Barcelona 08025, Spain
| | - Lluís Asmarats-Serra
- Cardiology Department, Hospital de la Santa Creu i Sant Pau. Carrer St. Antoni M. Claret 89, Barcelona 08025, Spain
| | - Álvaro Lambea-Gil
- Neurology Department, Hospital de la Santa Creu i Sant Pau. Carrer St. Antoni M. Claret 89, Barcelona 08025, Spain
| | - Garbiñe Ezcurra-Díaz
- Neurology Department, Hospital de la Santa Creu i Sant Pau. Carrer St. Antoni M. Claret 89, Barcelona 08025, Spain
| | - Dabit Arzamendi-Aizpurua
- Cardiology Department, Hospital de la Santa Creu i Sant Pau. Carrer St. Antoni M. Claret 89, Barcelona 08025, Spain
| | - Joan Martí-Fàbregas
- Neurology Department, Hospital de la Santa Creu i Sant Pau. Carrer St. Antoni M. Claret 89, Barcelona 08025, Spain
| |
Collapse
|
40
|
Goeldlin MB, Mueller M, Siepen BM, Zhang W, Ozkan H, Locatelli M, Du Y, Valenzuela W, Radojewski P, Hakim A, Kaesmacher J, Meinel TR, Clénin L, Branca M, Strambo D, Fischer T, Medlin F, Peters N, Carrera E, Lovblad KO, Karwacki GM, Cereda CW, Niederhauser J, Mono ML, Mueller A, Wegener S, Sartoretti S, Polymeris AA, Altersberger V, Katan M, Psychogios M, Sturzenegger R, Nauer C, Schaerer M, Buitrago Tellez C, Renaud S, Minkner Klahre K, Z'Graggen WJ, Bervini D, Bonati LH, Wiest R, Arnold M, Simister RJ, Wilson D, Jäger HR, Fischer U, Werring DJ, Seiffge DJ. CADMUS: A Novel MRI-Based Classification of Spontaneous Intracerebral Hemorrhage Associated With Cerebral Small Vessel Disease. Neurology 2024; 102:e207977. [PMID: 38165372 PMCID: PMC10834115 DOI: 10.1212/wnl.0000000000207977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Accepted: 10/04/2023] [Indexed: 01/03/2024] Open
Abstract
BACKGROUND AND OBJECTIVES Cerebral small vessel disease (SVD) is the major cause of intracerebral hemorrhage (ICH). There is no comprehensive, easily applicable classification of ICH subtypes according to the presumed underlying SVD using MRI. We developed an MRI-based classification for SVD-related ICH. METHODS We performed a retrospective study in the prospectively collected Swiss Stroke Registry (SSR, 2013-2019) and the Stroke InvestiGation in North And central London (SIGNAL) cohort. Patients with nontraumatic, SVD-related ICH and available MRI within 3 months were classified as Cerebral Amyloid angiopathy (CAA), Deep perforator arteriopathy (DPA), Mixed CAA-DPA, or Undetermined SVD using hemorrhagic and nonhemorrhagic MRI markers (CADMUS classification). The primary outcome was inter-rater reliability using Gwet's AC1. Secondary outcomes were recurrent ICH/ischemic stroke at 3 months according to the CADMUS phenotype. We performed Firth penalized logistic regressions and competing risk analyses. RESULTS The SSR cohort included 1,180 patients (median age [interquartile range] 73 [62-80] years, baseline NIH Stroke Scale 6 [2-12], 45.6% lobar hematoma, systolic blood pressure on admission 166 [145-185] mm Hg). The CADMUS phenotypes were as follows: mixed CAA-DPA (n = 751 patients, 63.6%), undetermined SVD (n = 203, 17.2%), CAA (n = 154, 13.1%), and DPA (n = 72, 6.3%), with a similar distribution in the SIGNAL cohort (n = 313). Inter-rater reliability was good (Gwet's AC1 for SSR/SIGNAL 0.69/0.74). During follow-up, 56 patients had 57 events (28 ICH, 29 ischemic strokes). Three-month event rates were comparable between the CADMUS phenotypes. DISCUSSION CADMUS, a novel MRI-based classification for SVD-associated ICH, is feasible and reproducible and may improve the classification of ICH subtypes in clinical practice and research.
Collapse
Affiliation(s)
- Martina B Goeldlin
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Madlaine Mueller
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Bernhard M Siepen
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Wenpeng Zhang
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Hatice Ozkan
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Martina Locatelli
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Yang Du
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Waldo Valenzuela
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Piotr Radojewski
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Arsany Hakim
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Johannes Kaesmacher
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Thomas R Meinel
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Leander Clénin
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Mattia Branca
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Davide Strambo
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Tim Fischer
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Friedrich Medlin
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Nils Peters
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Emmanuel Carrera
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Karl-Olof Lovblad
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Grzegorz M Karwacki
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Carlo W Cereda
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Julien Niederhauser
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Marie-Luise Mono
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Achim Mueller
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Susanne Wegener
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Sabine Sartoretti
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Alexandros A Polymeris
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Valerian Altersberger
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Mira Katan
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Marios Psychogios
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Rolf Sturzenegger
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Claude Nauer
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Michael Schaerer
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Carlos Buitrago Tellez
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Susanne Renaud
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Katharina Minkner Klahre
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Werner J Z'Graggen
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - David Bervini
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Leo H Bonati
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Roland Wiest
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Marcel Arnold
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Robert J Simister
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Duncan Wilson
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Hans Rolf Jäger
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - Urs Fischer
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - David J Werring
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| | - David J Seiffge
- From the Departments of Neurology (M.B.G., M.M., B.M.S., T.R.M., L.C., M.A., U.F., D.J.S., W.J.Z.G.) and Neurosurgery (D.B., W.J.Z.G.), and the University Institute for Diagnostic and Interventional Neuroradiology (W.V., P.R., A.H., J.K., R.W.), Inselspital Bern University Hospital and University of Bern; Graduate School for Health Sciences (M.B.G., B.M.S.) and CTU Bern (M.B.), University of Bern, Switzerland; Stroke Research Centre (M.B.G., W.Z., H.O., M.L., Y.D., D.J.W.), University College London Queen Square Institute of Neurology, United Kingdom; Service of Neurology (D.S.), Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne; Department of Radiology (T.F.), Cantonal Hospital St. Gallen; Department of Internal Medicine (F.M.), Stroke Unit and Division of Neurology, HFR Fribourg-Cantonal Hospital; Stroke Center Hirslanden (N.P.), Klinik Hirslanden Zurich; Stroke Research Group (E.C.), Department of Clinical Neurosciences, University Hospital and Faculty of Medicine, Geneva; Department of Radiology and Medical Informatics (K.-O.L.), University of Geneva; Department of Radiology and Nuclear Medicine (G.M.K.), Luzerner Kantonsspital; Stroke Center EOC (C.W.C.), Neurocenter of Southern Switzerland; Stroke Unit (J.N.), GHOL, Hôpital de zone de Nyon; Stadtspitäler Triemli und Waid (M.-L.M.), Zurich; Department of Neurology (A.M., S.W.), University Hospital and University of Zurich; Department of Radiology and Nuclear Medicine (S.S.), Kantonsspital Winterthur; Department of Neurology and Stroke Center (A.A.P., V.A., M.K., U.F., L.H.B.) and Center for Rehabilitation Rheinfelden (L.H.B.), University Hospital Basel and University of Basel; Diagnostic and Interventional Neuroradiology (M.P.), Department of Radiology and Nuclear Medicine, University Hospital Basel; Department of Neurology (R.S.), Kantonsspital Graubünden, Chur; Department of Radiology/Neuroradiology (C.N.), Kantonsspital Graubünden, Chur; Department of Neurology (M.S.), and Department of Radiology (C.B.T.), Buergerspital Solothurn; Division of Neurology (S.R.), Pourtalès Hospital, Neuchâtel; Department of Radiology (K.M.K.), Réseau Hospitalier Neuchâtelois, Switzerland; Comprehensive Stroke Service (R.J.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair & Rehabilitation, University College London Hospital, United Kingdom; and New Zealand Brain Research Institute (D.W.), Christchurch
| |
Collapse
|
41
|
Wang K, Zhang B, Du H, Duan H, Jiang Z, Fang S. Research landscape and trends of cerebral amyloid angiopathy: a 25-year scientometric analysis. Front Neurol 2024; 14:1334360. [PMID: 38259658 PMCID: PMC10800472 DOI: 10.3389/fneur.2023.1334360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2023] [Accepted: 12/15/2023] [Indexed: 01/24/2024] Open
Abstract
Background Cerebral amyloid angiopathy (CAA), a cerebral small vessel disease affecting leptomeningeal and cortical small blood vessels, is a common cause of spontaneous lobar intracerebral hemorrhage and cognitive impairment, particularly in elderly patients. This study aims to investigate the field of CAA research from a scientometric perspective. Methods Publications related to CAA from January 1st, 1999 to September 29th, 2023 were retrieved from the Web of Science Core Collection database. The scientometric software VOSviewer and CiteSpace were used to analyze and visualize the publication trends, countries/regions, institutions, authors, journals, cited references, and keywords of CAA. Results A total of 2,798 publications related to CAA from 73 countries/regions, led by the United States, were included. The number of publications showed an increasing trend over time. Massachusetts General Hospital was the most productive institution, and authors Greenberg and Charidimou published the most papers and were most frequently co-cited. Journal of Alzheimer's Disease was the most prolific journal in this field, and Neurology was the most co-cited journal. Apart from "cerebral amyloid angiopathy", the most frequently used keywords were "Alzheimer's disease", "amyloid beta", "intracerebral hemorrhage", and "dementia". The burst keywords in recent years included "cortical superficial siderosis" and "dysfunction". Conclusions This scientometric analysis provides a comprehensive overview of CAA research over the past 25 years, and offers important insights for future research directions and scientific decision-making in this field.
Collapse
Affiliation(s)
| | | | | | | | | | - Shaokuan Fang
- Department of Neurology, Neuroscience Research Center, The First Hospital of Jilin University, Changchun, China
| |
Collapse
|
42
|
Gennaro N, Ferroni E, Zorzi M, Denas G, Pengo V. ISCHEMIC STROKE AND MAJOR BLEEDING WHILE ON DIRECT ORAL ANTICOAGULANTS IN NAÏVE PATIENTS WITH ATRIAL FIBRILLATION: IMPACT OF RESUMPTION OR DISCONTINUATION OF ANTICOAGULANT TREATMENT. A population-based study. Int J Cardiol 2024; 394:131369. [PMID: 37722453 DOI: 10.1016/j.ijcard.2023.131369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Revised: 09/05/2023] [Accepted: 09/15/2023] [Indexed: 09/20/2023]
Abstract
AIMS We assessed the cumulative incidence of recurrent stroke, major bleeding and all-cause mortality associated with restarting antithrombotic treatment, in patients experiencing an anticoagulation-related event (stroke or major bleeding), occurred during anticoagulation therapy for AF. METHODS AND RESULTS We performed a retrospective population-based analysis on linked claims data of patients resident in the Veneto Region, treated with DOACs for AF and discharged (2013-2020) from the hospital for stroke, intracranial haemorrhage (ICH), and major bleeding. To adjust for competing risk of death and reduce confounding, we started the follow up after a 120-days blanking period, counting events in patients resuming oral anticoagulation versus those that did not. Risks of all-cause mortality, ischemic stroke (IS)intracranial haemorrhage (ICH), and other major bleeding events (MB) were estimated with multivariable Cox proportional hazard models and propensity score to adjust for differences in baseline characteristics. Overall, 1029 patients (mean age 77 years) were included in the final cohort: 23% experienced an IS, 18% an ICH, and 59% MB. Of these, 77% resumed anticoagulation. The cumulative incidence of events was significantly lower in patients resuming therapy. In the multivariable analysis considering age, sex and propensity score as covariates, resumption of anticoagulation significantly reduced the risk of a cumulative event (HR 0.45, 95%CI 0.35-0.57, p < 0.01). Stratifying for the index event, among patients with IS (92% resumed therapy), we observed a risk reduction of 81%; in patients with ICH (64% resumed therapy), we observed a risk reduction of 64% and for patients with MB (76% resuming therapy), we observed a risk reduction of 49%. CONCLUSIONS In patients with AF who experienced an anticoagulation-related event, resuming oral anticoagulation was associated with better outcomes for all-cause mortality and subsequent events as compared with patients who did not resume treatment.
Collapse
Affiliation(s)
- N Gennaro
- Epidemiological Department (SER), Azienda Zero of theVeneto Region. Padua. Italy
| | - E Ferroni
- Epidemiological Department (SER), Azienda Zero of theVeneto Region. Padua. Italy
| | - M Zorzi
- Epidemiological Department (SER), Azienda Zero of theVeneto Region. Padua. Italy
| | - G Denas
- Cardiology Clinic, Department of Cardiac. Thoracic, Vascular Sciences and Public Health. Padua University Hospital. Padua. Italy
| | - V Pengo
- Cardiology Clinic, Department of Cardiac. Thoracic, Vascular Sciences and Public Health. Padua University Hospital. Padua. Italy; Arianna Foundation on Anticoagulation. Bologna, Italy.
| |
Collapse
|
43
|
Li D, Sun Y, Ding L, Fu Y, Zhou J, Yu JT, Tan L. Associations of Growth-Associated Protein 43 with Cerebral Microbleeds: A Longitudinal Study. J Alzheimers Dis 2024; 97:1913-1922. [PMID: 38339928 DOI: 10.3233/jad-230508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2024]
Abstract
Background Cerebral microbleeds (CMB) play an important role in neurodegenerative pathology. Objective The present study aims to test whether cerebrospinal fluid (CSF) growth-associated protein 43 (GAP-43) level is linked to CMBs in elderly people. Methods A total of 750 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) who had measurements of GAP-43 and CMBs were included in the study. According to the presence and extent of CMBs, participants were stratified into different groups. Regression analyses were used to assess cross-sectional and longitudinal associations between GAP-43 and CMBs. Results Participants with CMB were slightly older and had higher concentrations of CSF GAP43. In multivariable adjusted analyses for age, gender, APOEɛ4 status, and cognitive diagnoses, higher CSF GAP-43 concentrations were modestly associated with CMB presence (OR = 1.169, 95% CI = 1.001-1.365) and number (β= 0.020, SE = 0.009, p = 0.027). Similarly, higher CSF GAP43 concentrations were accrual of CMB lesions, associated with higher CMB progression (OR = 1.231, 95% CI = 1.044-1.448) and number (β= 0.017, SE = 0.005, p = 0.001) in the follow up scan. In stratified analyses, slightly stronger associations were noted in male participants, those 65 years and older, carriers of APOEɛ4 alleles, and with more advanced cognitive disorders. Conclusions CSF GAP-43 was cross-sectionally associated with the presence and extent of CMBs. GAP-43 might be used as a biomarker to track the dynamic changes of CMBs in elderly persons.
Collapse
Affiliation(s)
- Da Li
- Department of Neurology, Qingdao Municipal Hospital, Nanjing Medical University, Nanjing, China
| | - Yan Sun
- Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China
| | - Lin Ding
- Department of Neurosurgery, Rizhao People's Hospital, Rizhao, China
| | - Yan Fu
- Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China
| | - Jie Zhou
- Department of Neurology, Qingdao Municipal Hospital, Nanjing Medical University, Nanjing, China
| | - Jin-Tai Yu
- Department of Neurology, Qingdao Municipal Hospital, Nanjing Medical University, Nanjing, China
- Department of Neurology and Institute of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai, China
| | - Lan Tan
- Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China
| |
Collapse
|
44
|
Goeldlin MB, Vynckier J, Mueller M, Drop B, Maamari B, Vonlanthen N, Siepen BM, Hakim A, Kaesmacher J, Jesse CM, Mueller MD, Meinel TR, Beyeler M, Clénin L, Gralla J, Z’Graggen W, Bervini D, Arnold M, Fischer U, Seiffge DJ. Small vessel disease burden and risk of recurrent cerebrovascular events in patients with lacunar stroke and intracerebral haemorrhage attributable to deep perforator arteriolopathy. Eur Stroke J 2023; 8:989-1000. [PMID: 37632398 PMCID: PMC10683739 DOI: 10.1177/23969873231193237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Accepted: 07/23/2023] [Indexed: 08/28/2023] Open
Abstract
INTRODUCTION Deep perforator arteriolopathy (DPA) causes intracerebral haemorrhage (ICH) and lacunar strokes (LS). We compare patient characteristics, MRI findings and clinical outcomes among patients with deep ICH and LS. PATIENTS AND METHODS We included patients with MRI-confirmed LS or ICH in the basal ganglia, thalamus, internal capsule or brainstem from the Bernese Stroke Registry. We assessed MRI small vessel disease (SVD) markers, SVD burden score, modified Rankin Scale (mRS) and ischaemic stroke or ICH at 3 months. RESULTS We included 716 patients, 117 patients (16.3%) with deep ICH (mean age (SD) 65.1 (±15.2) years, 37.1% female) and 599 patients (83.7%) with LS (mean age (SD) 69.7 (±13.6) years, 39.9% female). Compared to LS, deep ICH was associated with a higher SVD burden score (median (IQR) 2 (1-2) vs 1 (0-2)), aORshift 3.19, 95%CI 2.15-4.75). Deep ICH patients had more often cerebral microbleeds (deep ICH: 71.6% vs LS: 29.2%, p < 0.001, median count (IQR) 4(2-12) vs 2(1-6)) and a higher prevalence of lacunes (deep ICH: 60.5% vs LS: 27.4% p < 0.001). At 3 months, deep ICH was associated with higher mRS (aORshift 2.16, 95%CI 1.21-3.87). Occurrence of ischaemic stroke was numerically but not significantly higher in deep ICH (4.3% vs 2.9%; p = 0.51). One patient (1.1%) with ICH but none with LS suffered ICH recurrence. DISCUSSION/CONCLUSION DPA manifesting as ICH is associated with more severe MRI SVD burden and worse outcome compared to LS. The short-term risks of subsequent ischaemic stroke and recurrent ICH are similar in ICH and LS patients. This implies potential consequences for future secondary prevention strategies.
Collapse
Affiliation(s)
- Martina B Goeldlin
- Department of Neurology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
- Graduate School for Health Sciences, University of Bern, Bern, Switzerland
| | - Jan Vynckier
- Department of Neurology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
- Department of Neurology, Onze-Lieve-Vrouwziekenhuis Aalst, Aalst, Belgium
| | - Madlaine Mueller
- Department of Neurology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
- Graduate School for Health Sciences, University of Bern, Bern, Switzerland
| | - Boudewijn Drop
- Department of Neurology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
| | - Basel Maamari
- Department of Neurology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
| | - Noah Vonlanthen
- Department of Neurology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
| | - Bernhard M Siepen
- Department of Neurology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
- Graduate School for Health Sciences, University of Bern, Bern, Switzerland
| | - Arsany Hakim
- University Institute for Diagnostic and Interventional Neuroradiology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
| | - Johannes Kaesmacher
- University Institute for Diagnostic and Interventional Neuroradiology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
| | - Christopher Marvin Jesse
- Department of Neurosurgery, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
| | - Mandy D Mueller
- Department of Neurosurgery, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
| | - Thomas R Meinel
- Department of Neurology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
| | - Morin Beyeler
- Department of Neurology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
- Graduate School for Health Sciences, University of Bern, Bern, Switzerland
| | - Leander Clénin
- Department of Neurology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
| | - Jan Gralla
- University Institute for Diagnostic and Interventional Neuroradiology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
| | - Werner Z’Graggen
- Department of Neurology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
- Department of Neurosurgery, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
| | - David Bervini
- Department of Neurosurgery, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
| | - Marcel Arnold
- Department of Neurology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
| | - Urs Fischer
- Department of Neurology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
- Department of Neurology, University Hospital Basel, Basel, Switzerland
| | - David J Seiffge
- Department of Neurology, Inselspital Bern University Hospital and University of Bern, Bern, Switzerland
| |
Collapse
|
45
|
Al-Shahi Salman R, Greenberg SM. Antiplatelet Agent Use After Stroke due to Intracerebral Hemorrhage. Stroke 2023; 54:3173-3181. [PMID: 37916459 DOI: 10.1161/strokeaha.123.036886] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2023]
Abstract
This focused update about antiplatelet agents to reduce the high risk of major adverse cardiovascular events after stroke due to spontaneous (nontraumatic) intracerebral hemorrhage (ICH) complements earlier updates about blood pressure-lowering, lipid-lowering, and oral anticoagulation or left atrial appendage occlusion for atrial fibrillation after ICH. When used for secondary prevention in people without ICH, antiplatelet agents reduce the risk of major adverse cardiovascular event (rate ratio, 0.81 [95% CI, 0.75-0.87]) and might increase the risk of ICH (rate ratio, 1.67 [95% CI, 0.97-2.90]). Before 2019, guidance for clinical decisions about antiplatelet agent use after ICH has focused on estimating patients' predicted absolute risks and severities of ischemic and hemorrhagic major adverse cardiovascular event and applying the known effects of these drugs in people without ICH to estimate whether individual ICH survivors in clinical practice might be helped or harmed by antiplatelet agents. In 2019, the main results of the RESTART (Restart or Stop Antithrombotics Randomized Trial) randomized controlled trial including 537 survivors of ICH associated with antithrombotic drug use showed, counterintuitively, that antiplatelet agents might not increase the risk of recurrent ICH compared to antiplatelet agent avoidance over 2 years of follow-up (12/268 [4%] versus 23/268 [9%]; adjusted hazard ratio, 0.51 [95% CI, 0.25-1.03]; P=0.060). Guidelines in the United States, Canada, China, and the United Kingdom and Ireland have classified the level of evidence as B and indicated that antiplatelet agents may be considered/reasonable after ICH associated with antithrombotic agent use. Three subsequent clinical trials have recruited another 174 participants with ICH, but they will not be sufficient to determine the effects of antiplatelet therapy on all major adverse cardiovascular events reliably when pooled with RESTART. Therefore, ASPIRING (Antiplatelet Secondary Prevention International Randomized Study After Intracerebral Hemorrhage) aims to recruit 4148 ICH survivors to determine the effects of antiplatelet agents after ICH definitively overall and in subgroups.
Collapse
Affiliation(s)
| | - Steven M Greenberg
- Massachusetts General Hospital and Harvard Medical School, Boston (S.M.G.)
| |
Collapse
|
46
|
Jia X, Bo M, Zhao H, Xu J, Pan L, Lu Z. Risk factors for recurrent cerebral amyloid angiopathy-related intracerebral hemorrhage. Front Neurol 2023; 14:1265693. [PMID: 38020625 PMCID: PMC10661374 DOI: 10.3389/fneur.2023.1265693] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2023] [Accepted: 10/23/2023] [Indexed: 12/01/2023] Open
Abstract
Background Cerebral amyloid angiopathy (CAA) is the most common cause of lobar intracerebral hemorrhage (ICH) in the elderly, and its multifocal and recurrent nature leads to high rates of disability and mortality. Therefore, this study aimed to summarize the evidence regarding the recurrence rate and risk factors for CAA-related ICH (CAA-ICH). Methods We performed a systematic literature search of all English studies published in PubMed, Embase, Web of Science, Cochrane Library, Scopus, and CINAHL from inception to June 10, 2023. Studies reporting CAA-ICH recurrence rates and risk factors for CAA-ICH recurrence were included. We calculated pooled odds ratios (ORs) with their corresponding 95% confidence intervals (CIs) using a random/fixed-effects model based on the I2 assessment of heterogeneity between studies. Publication bias was assessed using Egger's test. Results Thirty studies were included in the final analysis. Meta-analysis showed that the recurrence rate of CAA-ICH was 23% (95% CI: 18-28%, I2 = 96.7%). The risk factors significantly associated with CAA-ICH recurrence were: previous ICH (OR = 2.03; 95% CI: 1.50-2.75; I2 = 36.8%; N = 8), baseline ICH volume (OR = 1.01; 95% CI: 1-1.02; I2 = 0%; N = 4), subarachnoid hemorrhage (cSAH) (OR = 3.05; 95% CI: 1.86-4.99; I2 = 0%; N = 3), the presence of cortical superficial siderosis (cSS) (OR = 2.04; 95% CI: 1.46-2.83; I2 = 0%; N = 5), disseminated cSS (OR = 3.21; 95% CI: 2.25-4.58; I2 = 16.0%; N = 6), and centrum semiovale-perivascular spaces (CSO-PVS) severity (OR = 1.67; 95% CI: 1.14-2.45; I2 = 0%; N = 4). Conclusion CAA-ICH has a high recurrence rate. cSAH, cSS (especially if disseminated), and CSO-PVS were significant markers for recurrent CAA-ICH. The onset of ICH in patients with CAA is usually repeated several times, and recurrence is partly related to the index ICH volume. Identifying clinical and neuroimaging predictors of CAA-ICH recurrence is of great significance for evaluating outcomes and improving the prognosis of patients with CAA-ICH. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=400240, identifier [CRD42023400240].
Collapse
Affiliation(s)
- Xinglei Jia
- VIP Department, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Menghan Bo
- VIP Department, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Hong Zhao
- Teaching Affairs Department, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Jia Xu
- VIP Department, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Luqian Pan
- Department of Geriatrics, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Zhengyu Lu
- VIP Department, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| |
Collapse
|
47
|
Ikeda S, Saito S, Hosoki S, Tonomura S, Yamamoto Y, Ikenouchi H, Ishiyama H, Tanaka T, Hattori Y, Friedland RP, Carare RO, Kuriyama N, Yakushiji Y, Hara H, Koga M, Toyoda K, Nomura R, Takegami M, Nakano K, Ihara M. Harboring Cnm-expressing Streptococcus mutans in the oral cavity relates to both deep and lobar cerebral microbleeds. Eur J Neurol 2023; 30:3487-3496. [PMID: 36708081 DOI: 10.1111/ene.15720] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2022] [Revised: 10/03/2022] [Accepted: 01/26/2023] [Indexed: 01/29/2023]
Abstract
BACKGROUND Cerebral microbleeds (CMBs) influence long-term prognoses of stroke patients. Streptococcus mutans expressing the collagen-binding protein Cnm induces cerebrovascular inflammation, impairing blood brain barrier integrity and causing cerebral bleeding. Here, we examine the association of Cnm-positive S. mutans with CMBs. METHODS Acute stroke patients were selected from a single-center registry database. Oral carriage of Cnm-positive or Cnm-negative S. mutans was determined using polymerase chain reaction assays. The associations of Cnm-positive S. mutans with CMB number and specifically the presence of >10 CMBs were examined using quasi-Poisson and logistic regression models, respectively. RESULTS This study included 3154 stroke patients, of which 428 patients (median [interquartile range] age, 73.0 [63.0-81.0] years; 269 men [62.9%]) underwent oral bacterial examinations. In total, 326 patients harbored S. mutans. After excluding four patients without imaging data, we compared patients with Cnm-positive (n = 72) and Cnm-negative (n = 250) S. mutans. Harboring Cnm-positive S. mutans was independently associated with the presence of >10 CMBs (adjusted odds ratio 2.20 [1.18-4.10]) and higher numbers of deep and lobar CMBs (adjusted risk ratio 1.61 [1.14-2.27] for deep; 5.14 [2.78-9.51] for lobar), but not infratentorial CMBs, after adjusting for age, sex, hypertension, stroke type, National Institutes of Health Stroke Scale score, and cerebral amyloid angiopathy. CONCLUSIONS Harboring Cnm-positive S. mutans was independently associated with a higher number of CMBs in deep and lobar locations. Reducing Cnm-positive S. mutans in the oral cavity may serve as a novel therapeutic approach for stroke.
Collapse
Affiliation(s)
- Shuhei Ikeda
- Department of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan
- Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan
- Division of Neurology, Department of Internal Medicine, Saga University Faculty of Medicine, Saga, Japan
| | - Satoshi Saito
- Department of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan
- Department of Pediatric Dentistry, Osaka University Graduate School of Dentistry, Suita, Japan
- Clinical and Experimental Sciences, University of Southampton, Southampton, UK
| | - Satoshi Hosoki
- Department of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Shuichi Tonomura
- Department of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan
- Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Yumi Yamamoto
- Department of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Hajime Ikenouchi
- Department of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Hiroyuki Ishiyama
- Department of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Tomotaka Tanaka
- Department of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Yorito Hattori
- Department of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Robert P Friedland
- Department of Neurology, University of Louisville, Louisville, Kentucky, USA
| | - Roxana O Carare
- Clinical and Experimental Sciences, University of Southampton, Southampton, UK
| | - Nagato Kuriyama
- Shizuoka Graduate University of Public Health, Shizuoka, Japan
- Department of Epidemiology for Community Health and Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Yusuke Yakushiji
- Division of Neurology, Department of Internal Medicine, Saga University Faculty of Medicine, Saga, Japan
- Department of Neurology, Kansai Medical University Medical Center, Hirakata, Japan
| | - Hideo Hara
- Division of Neurology, Department of Internal Medicine, Saga University Faculty of Medicine, Saga, Japan
| | - Masatoshi Koga
- Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Kazunori Toyoda
- Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Ryota Nomura
- Department of Pediatric Dentistry, Osaka University Graduate School of Dentistry, Suita, Japan
- Department of Pediatric Dentistry, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan
| | - Misa Takegami
- Department of Preventive Medicine and Epidemiology, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Kazuhiko Nakano
- Department of Pediatric Dentistry, Osaka University Graduate School of Dentistry, Suita, Japan
| | - Masafumi Ihara
- Department of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan
| |
Collapse
|
48
|
Shoamanesh A. Anticoagulation in patients with cerebral amyloid angiopathy. Lancet 2023; 402:1418-1419. [PMID: 37839419 DOI: 10.1016/s0140-6736(23)02025-1] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Accepted: 09/18/2023] [Indexed: 10/17/2023]
Affiliation(s)
- Ashkan Shoamanesh
- Department of Medicine, Population Health Research Institute, McMaster University, Hamilton, Canada.
| |
Collapse
|
49
|
Zhao J, Rostgaard K, Lauwers E, Dahlén T, Ostrowski SR, Erikstrup C, Pedersen OB, de Strooper B, Lemmens R, Hjalgrim H, Edgren G. Intracerebral Hemorrhage Among Blood Donors and Their Transfusion Recipients. JAMA 2023; 330:941-950. [PMID: 37698562 PMCID: PMC10498336 DOI: 10.1001/jama.2023.14445] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Accepted: 07/13/2023] [Indexed: 09/13/2023]
Abstract
Importance Recent reports have suggested that cerebral amyloid angiopathy, a common cause of multiple spontaneous intracerebral hemorrhages (ICHs), may be transmissible through parenteral injection of contaminated cadaveric pituitary hormone in humans. Objective To determine whether spontaneous ICH in blood donors after blood donation is associated with development of spontaneous ICH in transfusion recipients. Design, Setting, and Participants Exploratory retrospective cohort study using nationwide blood bank and health register data from Sweden (main cohort) and Denmark (validation cohort) and including all 1 089 370 patients aged 5 to 80 years recorded to have received a red blood cell transfusion from January 1, 1970 (Sweden), or January 1, 1980 (Denmark), until December 31, 2017. Exposures Receipt of red blood cell transfusions from blood donors who subsequently developed (1) a single spontaneous ICH, (2) multiple spontaneous ICHs, or (3) no spontaneous ICH. Main Outcomes and Measures Spontaneous ICH in transfusion recipients; ischemic stroke was a negative control outcome. Results A total of 759 858 patients from Sweden (median age, 65 [IQR, 48-73] years; 59% female) and 329 512 from Denmark (median age, 64 [IQR, 50-73] years; 58% female) were included, with a median follow-up of 5.8 (IQR, 1.4-12.5) years and 6.1 (IQR, 1.5-11.6) years, respectively. Patients who underwent transfusion with red blood cell units from donors who developed multiple spontaneous ICHs had a significantly higher risk of a single spontaneous ICH themselves, compared with patients receiving transfusions from donors who did not develop spontaneous ICH, in both the Swedish cohort (unadjusted incidence rate [IR], 3.16 vs 1.12 per 1000 person-years; adjusted hazard ratio [HR], 2.73; 95% CI, 1.72-4.35; P < .001) and the Danish cohort (unadjusted IR, 2.82 vs 1.09 per 1000 person-years; adjusted HR, 2.32; 95% CI, 1.04-5.19; P = .04). No significant difference was found for patients receiving transfusions from donors who developed a single spontaneous ICH in the Swedish cohort (unadjusted IR, 1.35 vs 1.12 per 1000 person-years; adjusted HR, 1.06; 95% CI, 0.84-1.36; P = .62) nor the Danish cohort (unadjusted IR, 1.36 vs 1.09 per 1000 person-years; adjusted HR, 1.06; 95% CI, 0.70-1.60; P = .73), nor for ischemic stroke as a negative control outcome. Conclusions and Relevance In an exploratory analysis of patients who received red blood cell transfusions, patients who underwent transfusion with red blood cells from donors who later developed multiple spontaneous ICHs were at significantly increased risk of spontaneous ICH themselves. This may suggest a transfusion-transmissible agent associated with some types of spontaneous ICH, although the findings may be susceptible to selection bias and residual confounding, and further research is needed to investigate if transfusion transmission of cerebral amyloid angiopathy might explain this association.
Collapse
Affiliation(s)
- Jingcheng Zhao
- Department of Medicine, Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden
| | - Klaus Rostgaard
- Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
- Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Elsa Lauwers
- VIB Center for Brain and Disease Research, Leuven, Belgium
| | - Torsten Dahlén
- Department of Medicine, Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden
- Hematology Department, Karolinska University Hospital, Stockholdm, Sweden
| | - Sisse Rye Ostrowski
- Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Christian Erikstrup
- Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
| | - Ole Birger Pedersen
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark
| | - Bart de Strooper
- VIB Center for Brain and Disease Research, Leuven, Belgium
- Laboratory for the Research of Neurodegenerative Diseases, Department of Neurosciences, Leuven Brain Institute, KU Leuven (University of Leuven), Leuven, Belgium
- Dementia Research Institute, University College London, London, England
| | - Robin Lemmens
- VIB Center for Brain and Disease Research, Leuven, Belgium
- Laboratory for the Research of Neurodegenerative Diseases, Department of Neurosciences, Leuven Brain Institute, KU Leuven (University of Leuven), Leuven, Belgium
- Department of Neurology, University Hospitals Leuven, Leuven, Belgium
| | - Henrik Hjalgrim
- Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
- Danish Cancer Society Research Center, Copenhagen, Denmark
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Department of Hematology, Rigshospitalet, Copenhagen, Denmark
| | - Gustaf Edgren
- Department of Medicine, Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden
- Department of Cardiology, Södersjukhuset, Stockholm, Sweden
| |
Collapse
|
50
|
Hindsholm MF, Damgaard D, Gurol ME, Gaist D, Simonsen CZ. Management and Prognosis of Acute Stroke in Atrial Fibrillation. J Clin Med 2023; 12:5752. [PMID: 37685819 PMCID: PMC10489015 DOI: 10.3390/jcm12175752] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2023] [Revised: 08/25/2023] [Accepted: 09/01/2023] [Indexed: 09/10/2023] Open
Abstract
Atrial fibrillation (AF) is an important risk factor for ischemic stroke (IS). Oral anticoagulation (OAC) significantly reduces the risk of IS in AF but also increases the risk of systemic bleeding, including intracerebral hemorrhage (ICH). AF-related strokes are associated with greater disability and mortality compared to non-AF strokes. The management of patients with AF-related strokes is challenging, and it involves weighing individual risks and benefits in the acute treatment and preventive strategies of these patients. This review summarizes the current knowledge of the acute management of ischemic and hemorrhagic stroke in patients with AF, and the prognosis and potential implications for management both in the acute and long-term setting.
Collapse
Affiliation(s)
- Mette F. Hindsholm
- Department of Neurology, Aarhus University Hospital, 8200 Aarhus, Denmark; (D.D.); (C.Z.S.)
- Department of Clinical Medicine, Aarhus University, 8200 Aarhus, Denmark
| | - Dorte Damgaard
- Department of Neurology, Aarhus University Hospital, 8200 Aarhus, Denmark; (D.D.); (C.Z.S.)
| | - M. Edip Gurol
- Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA;
- Harvard Medical School, Boston, MA 02115, USA
| | - David Gaist
- Research Unit for Neurology, Odense University Hospital, University of Southern Denmark, 5000 Odense, Denmark;
| | - Claus Z. Simonsen
- Department of Neurology, Aarhus University Hospital, 8200 Aarhus, Denmark; (D.D.); (C.Z.S.)
- Department of Clinical Medicine, Aarhus University, 8200 Aarhus, Denmark
| |
Collapse
|